Rhinovirus vaccines

By using RV VP0 peptide or its encoded polynucleotide as an immunogenic composition, the problem of antigen heterogeneity in rhinovirus vaccine development was solved, and a wide range of immune responses to a variety of rhinovirus strains was achieved, providing effective prevention and treatment options.

CN119072331APending Publication Date: 2024-12-03IP2IPO INNOVATIONS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380023972.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-28
Filing Date
2023-02-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing rhinovirus (RV) vaccine development faces antigen heterogeneity issues, resulting in a lack of effective anti-RV treatments and vaccines, and the differences between rhinovirus strains hinder the widespread applicability of the vaccine.

Method used

Using RV VP0 peptide or its encoded polynucleotide as an immunogenic composition, RV VP0 protein was identified through in-depth bioinformatic analysis, which was used to trigger cross-strain cellular immune responses, covering a variety of rhinovirus strains, including RV -A, RV-B and RV-C.

Benefits of technology

A wide range of cross-reactive immune responses to a variety of rhinovirus strains has been achieved, the problem of antigen heterogeneity has been overcome, and effective prevention and treatment plans for rhinovirus infection have been provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072331A_ABST
    Figure CN119072331A_ABST
Patent Text Reader

Abstract

The present invention relates to immunogenic compositions, in particular to immunogenic compositions for preventing, treating or ameliorating human rhinovirus (RV) infection. The present invention relates, inter alia, to RV VP0 peptides (or proteins) and polynucleotides encoding such peptides, and their use in immunogenic compositions for eliciting immune responses and preventing rhinovirus infections.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to immunogenic compositions, and in particular to immunogenic compositions for preventing, treating or ameliorating human rhinovirus (RV) infection. The present invention particularly relates to RV VP0 peptides (or proteins) and polynucleotides encoding such peptides, and their use in immunogenic compositions for eliciting immune responses and preventing rhinovirus infection.

[0002] Rhinoviruses (RV) are picornaviruses, small single-stranded RNA viruses with a genome size of approximately 6.8 Kb to 7.2 Kb [1]. RV are the main cause of the common cold, early childhood viral wheezing illnesses, and acute exacerbations (exacerbations) of lung diseases such as asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and chronic fibrotic lung disease [2, 3]. RV are responsible for approximately 75% to 90% of these illnesses.

[0003] There is currently no effective treatment for RV and no vaccine against RV. The major obstacle to RV vaccine development is the large number of genetically and antigenically distinct circulating strains. Recent studies estimate that there are approximately 180 genetically distinct RV strains in circulation [4]. These strains are divided into three types based on their genomic identity: RV-A, RV-B, and RV-C [1, 5]. RV-A and RV-C are the largest species in terms of number and are the most important in terms of clinical disease, with RV-A and RV-C being responsible for the majority of exacerbations of asthma and COPD and wheezing illness leading to hospitalization in children. However, RV-B has also been associated with an increased risk of wheezing illness [7].

[0004] Therefore, there is a need to provide immunogenic compositions that are capable of protecting individuals against many, if not all, strains of RV.

[0005] Using in-depth bioinformatics analysis, the inventors identified RV VP0 proteins from a single representative strain that, when used as vaccine immunogens, surprisingly elicited cellular immunity against all other members of this RV species.

[0006] Therefore, according to a first aspect of the present invention, an immunogenic composition is provided, comprising at least one isolated human rhinovirus (RV) VP0 peptide, or an isolated polynucleotide encoding the peptide, wherein the peptide is selected from the group consisting of: RV-C VP0 peptide; RV-B VP0 peptide; RV-A28 VP0; and RV-A89 VP0, or variants or fragments thereof.

[0007] As shown in the Examples, the inventors surprisingly found that the novel rhinovirus immunogens can induce a broad cellular immune response that cross-reacts with other RV strains of the same species. Figure 4 , 8As shown in Figures 1 and 9, splenocytes from mice immunized with RV-B06 VP0 cross-react with VP0 peptides from other RV-B species members, and splenocytes from mice immunized with RV-C19 VP0 or RV-C24 VP0 cross-react with VP0 peptides from other RV-C species members, respectively. In addition, the inventors have demonstrated that immunization with mRNA encoding RV VP0 peptides induces a broad range of cellular immune responses. For example, Fig.15 As shown, the inventors demonstrated that immunization of mice with RV-C24 VP0 mRNA induces cellular immunity that cross-reacts with other members of the C class of RV. Thus, advantageously, the immunogenic composition according to the present invention overcomes the problem of antigenic heterogeneity between RV strains, which has severely hampered the development of RV vaccines to date.

[0008] In a preferred embodiment, the immunogenic composition includes the RV-C VPO peptide.

[0009] In another preferred embodiment, the immunogenic composition comprises the RV-B VPO peptide.

[0010] In another preferred embodiment, the immunogenic composition comprises RV-A28 VPO and / or RV-A89 VPO.

[0011] Alternatively, in another embodiment, the immunogenic composition comprises at least two isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-CVP0 peptide; RV-BVP0 peptide; RV-A28 VP0; and RV-A89 VP0.

[0012] In another preferred embodiment, the immunogenic composition comprises at least three isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-CVP0 peptide; RV-B VP0 peptide; RV-A28 VP0; and RV-A89 VP0.

[0013] Preferably, the RV-C VP0 peptide is selected from the group consisting of: RV-C07 VP0; RV-C19 VP0; RV-C24 VP0; and RV-C01 VP0, or variants or fragments thereof.

[0014] Preferably, the RV-B VP0 peptide is RV-B06 VP0.

[0015] Therefore, in one embodiment, the immunogenic composition preferably includes at least two isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-A28; RV-A89; RV-B06 VP0; RV-C07 VP0; RV-C19 VP0; RV-C24 VP0; and RV-C01 VP0, or variants or fragments thereof.

[0016] Alternatively, the immunogenic composition preferably includes at least three isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-A28; RV-A89; RV-B06 VP0; RV-C07 VP0; RV-C19 VP0; RV-C24 VP0; and RV-C01 VP0, or variants or fragments thereof.

[0017] Alternatively, the immunogenic composition preferably comprises at least four isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-A28; RV-A89; RV-B06 VP0; RV-C07 VP0; RV-C19 VP0; RV-C24 VP0; and RV-C01 VP0, or variants or fragments thereof.

[0018] Alternatively, the immunogenic composition comprises at least five isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-A28; RV-A89; RV-B06VP0; RV-C07VP0; RV-C19 VP0; RV-C24 VP0; and RV-C01 VP0, or variants or fragments thereof.

[0019] Alternatively, the immunogenic composition comprises at least six isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-A28; RV-A89; RV-B06VP0; RV-C07VP0; RV-C19 VP0; RV-C24 VP0; and RV-C01 VP0, or variants or fragments thereof.

[0020] Alternatively, the immunogenic composition comprises at least seven isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-A28; RV-A89; RV-B06VP0; RV-C07VP0; RV-C19 VP0; RV-C24 VP0; and RV-C01 VP0, or variants or fragments thereof.

[0021] In one embodiment, the immunogenic composition may further include an isolated RV-A16 VP0 peptide and / or an isolated RV-A29 VP0 peptide, or an isolated polynucleotide encoding the peptides, or a variant or fragment thereof.

[0022] In a preferred embodiment, the immunogenic composition according to the first aspect comprises three isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-A16 VP0; RV-B06 VP0RV; and RV-C24 VP0, or variants or fragments thereof.

[0023] It is well known to the skilled person that there are three different types of rhinoviruses: rhinovirus A (RV-A), also known as class A rhinovirus; rhinovirus B (RV-B), also known as class B rhinovirus; and rhinovirus C (RV-C), also known as class C rhinovirus. RVs are also classified into strains based on their nucleotide sequence homology. As used herein, the term "strain" refers to a subphylum within a rhinovirus and depends on the VP1 gene sequence of the rhinovirus. For example, the terms RV-A16, RV-A28, RV-A29, RV-A89, RV-B06, RV-C07, RV-C19, RV-C24, and RV-C01 refer to RV strains. RVs have been classified based on several other parameters, including receptor specificity and antiviral sensitivity.

[0024] RV has a 25nm capsid with icosahedral symmetry, composed of 60 copies of each of the four virus-encoded proteins (VP1, VP2, VP3 and VP4), and encapsulates a single-stranded RNA genome of approximately 7500 nucleotides. The RNA has positive polarity, is polyadenylated at its 3' end, and is covalently bound to the small protein VPg at its 5' end. The major translation product of this RNA is a single "large" polyprotein, which is divided into three smaller polyproteins P1, P2 and P3, which are then processed by proteolytic cleavage to produce mature viral proteins. The P1 polyprotein consists of four peptides (1A or VP4, 1B or VP2, 1C or VP3 and 1D or VP1), the P2 polyprotein consists of three peptides (2A, 2B and 2C), and the P3 polyprotein consists of four peptides (3A, 3B, 3C and 3D). 2A and 3C are viral proteases, while 3D corresponds to the viral RNA polymerase. The P1 polyprotein is a precursor for the production of the four structural proteins of the nucleocapsid. First, the P1 polyprotein is cleaved to produce the VP0 polyprotein, which contains the amino acid sequences of the VP4 and VP2 peptides, the VP3 peptide and the VP1 peptide. After the virus is assembled, the VP0 polyprotein is cleaved into the VP4 peptide and the VP2 peptide.

[0025] It will be well known to the skilled person that the terms "VP0 polyprotein", "VP0 peptide" or "peptide 1AB" refer to a protein precursor derived from the RV P1 polyprotein, which consists of the amino acid sequences of the VP4 and VP2 peptides. The length of the VP0 polyprotein is generally about 330 amino acids. The amino acid sequence of the VP0 polyprotein varies slightly depending on the RV strain or species.

[0026] Thus, a fragment of the RV VP0 peptide may comprise or consist of the corresponding VP2 peptide and / or VP4 peptide. Thus, a fragment of the RV VP0 may be at least 1, 2, 3, 4, 5, 10, 20, 25, 30, 45, 50, 60, 70, 80, 90 or 100 amino acids less than the full-length RV VP0 described herein.

[0027] In one embodiment, the peptide and variants or fragments thereof comprise or consist of at least 40 amino acids, at least 45 amino acids, at least 50 amino acids, at least 55 amino acids, at least 60 amino acids, at least 65 amino acids, at least 66 amino acids, at least 67 amino acids, at least 68 amino acids or at least 69 amino acids.

[0028] In another embodiment, the peptide and variants or fragments thereof comprise, or consist of, at least 70 amino acids, at least 80 amino acids, at least 90 amino acids, at least 100 amino acids, at least 110 amino acids, at least 120 amino acids, at least 130 amino acids, at least 140 amino acids, at least 150 amino acids, at least 160 amino acids, at least 170 amino acids, at least 180 amino acids, at least 190 amino acids, at least 200 amino acids, at least 210 amino acids, at least 220 amino acids, at least 230 amino acids, at least 240 amino acids, at least 250 amino acids, at least 255 amino acids, at least 260 amino acids, at least 261 amino acids, at least 262 amino acids, at least 263 amino acids, at least 264 amino acids, at least 265 amino acids, at least 266 amino acids, or at least 267 amino acids.

[0029] In another embodiment, the peptide and variants or fragments thereof comprise or consist of at least 280 amino acids, at least 290 amino acids, at least 300 amino acids, at least 310 amino acids, at least 320 amino acids, or at least 330 amino acids.

[0030] As used herein, the term "isolated" means removed from its natural environment, i.e., from a rhinovirus or a cell infected by a rhinovirus. Generally, it refers to a peptide or nucleic acid that is substantially free of cellular material, bacterial material, viral material, or culture medium when produced by recombinant DNA techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

[0031] In one embodiment, at least two or more of the RV VP0 peptides can form a fusion peptide or protein. It is well known to the skilled person that a fusion peptide / protein is a peptide comprising all or part of the amino acid sequence of at least two or more individual peptide units linked together by covalent bonds, such as by peptide (amide) bonds. Two or more peptides can be directly linked to each other or can be linked using a connecting sequence. In another embodiment, at least three, four, five or more of the RV VP0 peptides can form a fusion peptide. Alternatively, multiple RV VP0 peptides can be stored as separate peptides but used simultaneously, i.e., not fused together.

[0032] The present invention also relates to an immunogenic composition comprising an isolated polynucleotide encoding an isolated human rhinovirus (RV) VP0 peptide.

[0033] In a preferred embodiment, the polynucleotide comprises a nucleic acid sequence encoding a peptide. Preferably, the nucleic acid sequence is controlled by elements necessary for its expression in mammalian cells (particularly human cells). The nucleic acid sequence can be incorporated into a plasmid, which can be further formulated in a delivery vehicle such as a liposome to facilitate its introduction into a host cell.

[0034] As used herein, the term "nucleic acid" includes DNA and RNA, such as messenger RNA (mRNA) or self-amplifying RNA (saRNA), and can be double-stranded or single-stranded. Most preferably, the nucleic acid is mRNA.

[0035] As used herein, the expression "elements necessary for expression in mammalian cells" is understood to refer to all elements that allow transcription of DNA or DNA fragments into mRNA or saRNA and translation of the latter into proteins in mammalian cells (such as human cells). Typically, the elements necessary for expressing nucleic acids in mammalian cells include a promoter that functions in selected mammalian cells, which may be constitutive or inducible; a ribosome binding site; a start codon (ATG), if necessary; a region encoding a signal peptide (e.g., a lipidated signal peptide); a stop codon; and a 3' terminal region (translation and / or transcription terminator). Other transcription control elements, such as enhancers, operators, and repressors, may also be operably associated with polynucleotides to direct transcription and / or translation into cells. The signal peptide coding region is preferably adjacent to the nucleic acid included in the immunogenic composition of the present invention and is placed in an appropriate reading frame. The signal peptide coding region may be homologous or heterologous to the DNA molecule encoding the mature peptide or fusion peptide of the present invention, and may be specific to the secretion apparatus of the host for expression. The open reading frame composed of the nucleic acid alone or together with the signal peptide included in the immunogenic composition of the present invention is controlled by a promoter so that transcription and translation occur in the host system. Promoters (and signal peptide coding regions) are well known and available to those skilled in the art.

[0036] The nucleic acid sequence may be codon optimized to enhance transcription of the DNA encoding the peptide and / or fusion peptide of the present invention and / or to prolong translation of the mRNA encoding the peptide and / or fusion peptide.

[0037] The immunogenic composition may include a concatemer of isolated polynucleotides encoding RV VPO peptides. In a preferred embodiment, the polynucleotide encoding the RV VPO peptide is mRNA. Therefore, in one embodiment, the immunogenic composition includes isolated polynucleotides encoding at least two or more of the RV VPO peptides. In another embodiment, the polynucleotide encodes at least three, four, five or more of the RV VPO peptides. Alternatively, multiple RV VPO peptides may be encoded by multiple separate polynucleotides, but used simultaneously, i.e., not fused together.

[0038] The inventors found that VP0 peptides from RV-A and RV-B species triggered a stronger immune response than VP0 peptides from the RV-C group. Therefore, the inventors believe that a concatemer in which the RV-C VP0 peptide is encoded first may be beneficial because this will allow more RV-C VPO peptides to be expressed. Therefore, in one embodiment, the nucleic acid sequence encoding the RV-C VP0 peptide is located 5' of the nucleic acid sequence encoding the RV-B VP0 peptide, the RV-A28 VP0 peptide and / or the RV-A89 VP0 peptide.

[0039] Alternatively, in another embodiment, the nucleic acid sequences encoding the RV-A VPO peptide, the RV-B VPO peptide, and the RV-C VPO peptide are arranged in any order.

[0040] In a preferred embodiment, the immunogenic composition comprises an isolated polynucleotide encoding the RV-C24 VPO peptide, an isolated polynucleotide encoding the RV-A16 VPO peptide and an isolated polynucleotide encoding the RV-B06 VPO peptide.Preferably, the polynucleotide encoding the RV VPO peptide is separated from the 2A peptide coding sequence.

[0041] In one embodiment, the amino acid sequence of the RV-A16 VP0 peptide is provided herein as SEQ ID No: 1, as follows:

[0042] MGAQVSRQNVGTHSTQNMVSNGSSLNYFNINYFKDAASSGASRLDFSQDPSKFTDPVKDVLEKGIPTLQSPSVEACGYSDRIIQITRGDSTITSQDVANAVVGYGVWPHYLTPQDATAIDKPTQPDTSSNRFYTLDSKMWNSTSKGWWWKLPDALKDMGIFGENM FYHFLGRSGYTVHVQCNASKFHQGTLLVVMIPEHQLATVNKGNVNAGYKYTHPGEAGREVGTQVENEKQPSDDNWLNFDGTLLGNLLIFPHQFINLRSNNSATLIVPYVNAVPMDSMVRHNNWSLVIIPVCQLQSNNISNIVPITVSISPMCAEFSGARAKTVVQ

[0043] [SEQ ID No:1]

[0044] Therefore, preferably, the RV-A16 VP0 peptide comprises an amino acid sequence substantially as set forth in SEQ ID No: 1, or a variant or fragment thereof.

[0045] The VP4 peptide of RV-A16 constitutes amino acid residues 1-69 of SEQ ID No: 1, and the VP2 peptide of RV-A16 constitutes amino acid residues 70-330 of SEQ ID No: 1. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-A16 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0046] In one embodiment, the RV-A16 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 2, as follows:

[0047] ATGGGTGCGCAGGTGAGCCGTCAGAACGTGGGCACCCATAGCACCCAGAACATGGTGAGCAACGGCAGCAGCCTGAACTATTTCAACATCAACTATTTCAAAGATGCGGCGAGCAGCGGTGCGAGCCGTCTGGATTTCAGCCAGGATCCGAGCAAATTTACCGATCCGGTGAAAGATGTGCTGGAAAAAGGCATTCCGACCCTGCAGAGCCCGAGCGTGGAAGCGTGCGGCTATAGCGATCGTATTATTCAGATTACCCGTGGCGATAGCACCATTACCAGCCAGGATGTGGCGAACGCGGTGGTGGGCTATGGTGTGTGGCCGCATTATCTGACCCCGCAGGATGCGACCGCGATTGATAAACCGACCCAGCCGGATACCAGCAGCAACCGTTTTTATACCCTGGATAGCAAAATGTGGAACAGCACCAGCAAAGGTTGGTGGTGGAAACTGCCGGATGCGCTGAAAGATATGGGCATTTTCGGCGAAAACATGTTCTATCATTTTCTGGGCCGTAGCGGCTATACCGTGCATGTGCAGTGCAACGCGAGCAAATTTCATCAGGGCACCCTGCTGGTTGTGATGATTCCGGAACATCAGCTGGCCACCGTGAACAAAGGCAACGTGAACGCGGGCTATAAATATACCCATCCGGGCGAAGCGGGTCGTGAAGTGGGCACCCAGGTGGAAAACGAAAAACAGCCGAGCGATGATAACTGGCTGAACTTTGATGGCACCCTGCTGGGCAACCTGCTGATTTTTCCGCATCAGTTCATTAACCTGCGTAGCAACAACAGCGCGACCCTGATTGTGCCGTATGTGAACGCGGTGCCGATGGATAGCATGGTGCGTCATAACAATTGGAGCCTGGTGATTATTCCGGTGTGCCAGCTGCAGAGCAACAACATTAGCAACATTGTGCCGATTACCGTGAGCATTAGCCCGATGTGCGCGGAATTTAGCGGTGCGCGTGCGAAAACCGTGGTGCAG

[0048] [SEQ ID No:2]

[0049] Thus, preferably, the RV-A16 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 2 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 2 or a variant or fragment thereof.

[0050] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 2 is provided herein as SEQ ID No: 3, as follows:

[0051] AUGGGUGCGCAGGUGAGCCGUCAGAACGUGGCACCCAUAGCACCCAGAACAUGGUGAGCAACGGCAGCAGCCUGAACUAUUUCAACACUAUUUCAAAAAGCGGCGAGCCGUGGCGAGCCGGUCUGGAUUUCAGCCGAGCGAUGCAAAUUUACCGAUCCGGUGGUAAAAGGCAUUCCCGACCCGAGCGUGGAAGCGUGGAAGCGUGCGGUCUUAUAGCGAAUAUAUACCGUGGCGAUAGCCACUAUAUACCAGCCAGGAUUGGCGAACGCGGUGGUGGCUAUAUAUUCUGACCCCGCAGGAUGCGAUCCGCGAUUGUAAAACCCGACCGACCGAGCCAGCCAGCCAACCGUUUUUAUACCCUGGAUAGCACCAGCAGCCAAGGUGGUGGUAUACCCUGGAUACCAGCCAAGCAAGGUGGUGGUAAACCCUGGAUACCAGCCAAGCAAGGUGGUGGUAAACUCCCGGAAUAGCGCAUGCAAAGGUUGGUGGUAACUCCGCGGAAUAGCGCAAGAUAUUGGGCAUUUUCGGCGAAAAACAUG UUCUAUAUUUUCUGGGCCGUAGCGGGCUAUACCGUGCAUGUGCAACGCGAGCAAAUUUCACAGGGCACCCUGCUGGUUGUGAUUCCGGAACAUACCAGCUGGCCACCGUGAACAAAGGCAACGUGAACGCGGCUAUAAAUAUACCCAUCCCGGGCGAGAGCGUGUGAGUGGGCACCCAGGUGGAAAACGAAAACAGCCGAGCGAUGAUAAACCUGGCUGAACUUUGGACACCCUGCUGGCAACCUGCUGGUAUUUCCGCAAUACAAUUGGACCUGAUUGUGCCGUAUUGUGGAACGCGGUGCCGAUGGAUAGCAUGGUGCCGUCAUAACAAUUGGACCUGGUAUAUUCCGAGCUAUAUAUUGGACCUGGUUGCGCAGAGCAACAACAAUUAGACAACAUAUUGGACCCUGGUGUGCGCAGCAGCACAAAAUUAGCAACAUUGUGGCCGAGCUGAGCCAACAACAUUAGCAACAUUGUGGCCGAUGAGCAUUAAGCCGUGAGCAUUAAUUACCGUGAGCAUUAUGCCCGAUGUGCGCGGAAUAUUAGCCGUGUGCGCGAAAUAUAGCGUGUGGCCGGAAAACCGUGUGGC

[0052] [SEQ ID No:3]

[0053] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 3, or a variant or fragment thereof.

[0054] In one embodiment, the amino acid sequence of the RV-B06 VP0 peptide is provided herein as SEQ ID No: 4, as follows:

[0055] MGAQVSTQKSGSHENQNILTNGSNQTFTVINYYKDAASSSSAGQSFSTDPSKFTEPVKDLMLKGAPALNSPNVEACGYSDRVQQITLGNSTITTQEAANAVVCYAEWPEYLPDGDASDVNKTSKPDTSVCRFYTLESKTWQNSSKGWCWKLPDALKDMGVFGQNM FFHSLGRSGYTIHVQCNATKFHSGCLLVVVIPEHQLASHKGGNVSVKYKYTHPGESGIDLSTQLDEDGPVKDPVYSMNGTLLGNLLIFPHQFINLRTNNTATIVVPYINSVPIDSMRHNNVSLLVIPIAPLVAPTGSPQTLPVTVTIAPMCTEFTGIRSKTIVPQ

[0056] [SEQ ID No:4]

[0057] Therefore, preferably, the RV-B06 VP0 peptide comprises an amino acid sequence substantially as set forth in SEQ ID No: 4, or a variant or fragment thereof.

[0058] The VP4 peptide of RV-B06 constitutes amino acid residues 1-69 of SEQ ID No: 4, and the VP2 peptide of RV-B06 constitutes amino acid residues 70-331 of SEQ ID No: 4. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-B06 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0059] In one embodiment, the RV-B06 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 5, as follows:

[0060] ATGGGCGCTCAAGTTTCAACACAAAAGAGTGGTTCTCACGAGAATCAGAACATCTTAACTAATGGCTCAAATCAGACGTTCACAGTTATAAATTATTATAAAGATGCAGCTAGCTCATCATCAGCAGGTCAGTCTTTCTCAACGGACCCATCAAAATTCACAGAACCAGTTAAAGACCTGATGTTGAAAGGTGCCCCAGCATTGAACTCACCAAATGTTGAAGCATGTGGTTATAGTGACAGAGTCCAACAAATTACTCTAGGTAATTCCACTATAACAACCCAGGAAGCAGCCAATGCGGTTGTGTGTTATGCTGAGTGGCCTGAATACTTGCCAGATGGTGATGCTAGTGATGTTAATAAGACTTCCAAACCAGACACATCTGTATGTAGATTCTACACATTGGAGAGTAAAACATGGCAAAACAGCTCAAAGGGATGGTGTTGGAAACTACCAGATGCTCTCAAGGATATGGGTGTGTTTGGGCAAAACATGTTCTTCCACTCGCTTGGTAGATCTGGCTATACTATACATGTGCAATGTAATGCAACTAAATTCCATAGTGGCTGTCTTCTTGTTGTTGTTATCCCAGAACACCAATTGGCATCTCACAAAGGCGGGAATGTGTCAGTGAAGTATAAATATACACATCCAGGAGAGAGTGGTATAGACTTGAGTACACAGTTAGATGAGGATGGTCCAGTGAAAGATCCTGTCTATAGCATGAATGGCACTCTATTAGGTAACTTACTCATCTTCCCTCACCAGTTTATCAACCTCAGAACAAACAATACAGCCACAATAGTTGTGCCATATATTAATTCAGTGCCAATAGACTCAATGACACGCCATAATAACGTGTCACTCTTAGTGATTCCCATAGCACCTCTAGTGGCTCCAACTGGATCACCACAAACACTTCCAGTGACAGTGACTATAGCTCCCATGTGTACAGAGTTCACGGGTATTAGATCAAAAACCATTGTTCCACAG

[0061] [SEQ ID No:5]

[0062] Thus, preferably, the RV-B06 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 5 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 5 or a variant or fragment thereof.

[0063] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 5 is provided herein as SEQ ID No: 6, as follows:

[0064] AUGGGCGCUCAAGUUUCAACACAAAAAGAGUGGUUCUCACGAGAAUCAACAUCUUACUAUAGGCUCAAAUACAGGUUCACAGUUAUAAUAUUAUAAAAGAUGCAGCUAGCUCAUCAGCAGUCUUUCUCAACGGACCAUCAAAAUAUUCACAGACCAGUUAAAAAAGCCUGAUGUUGGAAAAGGUGCCCCAGCAUUGACUACACCAAAUGUUGAGAUAGCUAGCUAGCUAUAUAACAACCCAGGAAGCCAAUGCGGUUGGUGUUAUGCUAGCUGAGUGCCUGAAUAUCUUGCCCAGAUGGUGAUGCUAGUGCUAGUGCUAGUGCUAGUGCUAGUGCUAGUGCUAGUGUAAUAAAAGACUUCCAAACCACACAAUGCGUAUGUGUUAAUAAGACUUCCAAACCACACAAUGGCUAGCUAUGUGUUGGAAUUAAAGACUUCUAACCAAUGGGUGUAUAUGAGUUAAACAAUGGGUGUU UCUUCCACUCGCUUGGUAGAUCUGGCUAUAUACAUAUACAUUGUGCAAUGUAAUUCCAUAGUGGCUGUCUUCUUGUGUGUUGUAUCCCCAGAACCAAUUGGCAUCUCACAAAGGCGGGAAUUGUGUCAGUGUAGUAGUAUAAAUAUAUACACAUCCACGAGAGAGAGUUGGUGUUAUAGACUUGAGUACACUUGAGUACACUGUAUAGCAUGAAUGGCACUCUAUUAUGGUACUAUUAGGUAACUUCCUCUCACACAGUUUAUCAACCUCAGAACAAACAAUACAGCCACAAUAUGUUGUGGCAUAUAUUAAUAUAUAUAUAUAUAUAUAUAUAUACUGGCCAAUAGACUCAAUGACACGCCAUAAUAACGUGUCACCUCUUAUGUGUCCACUUAUGUGUCCACUUAUGUGUCCACUUAAGUCACACCAAACACUUCAGUGUGUCCACUUAUGUAACCAGUGACUUAUAAGCUCCCAUGUGUCACAGGUUCACGGGUAUAUAUAGUAUAAAACCAAUUGUGUCCACUUAAGUAACCUAUUGUCCACGCUUAAGUAACCUAUUGUCCACGCUUAAGUAACCUAUUGUCCAGUGACUUAAGCUCCCAUGUGUCACAGGUUCACGGGUAUAUAUAGUAUAAAACCAAUUGUUCCACAGGUUCACAGGUUCACGGGUAUAUAGUAUAAAACCAAUUGUUCCACAGGUUCACAGGUUCACAGGUUCACAGGUUCACGGGUAUAUAGUAAAAAACCAAUUGUUCCACAGGUUCAC

[0065] [SEQ ID No:6]

[0066] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 6, or a variant or fragment thereof.

[0067] In one embodiment, the amino acid sequence of the RV-C07 VP0 peptide is provided herein as SEQ ID No: 7, as follows:

[0068] MGAQVSKQSVGAHETMVHAGSGAVVKYFNINYYKDAASSGLTKQDFSQDPSKFTQPVADLLTNPALMSPSVEACGYSDRLKQITIGSSTITTQDSVNTIVAYGEWPSYLSDLDASSVDKPTHPETSADRFYTLDSVRWGGSSKGWWWKLPDCLKNMGIFGQNMYY HAMGRSGYIIHTQCNATKFHSGCLLVAVVPEHQLAYIGGTNAQVSYKHTHPGHEIGNTSRGDNRPDEDPFFNCNGTLLGNLTIFPHQLINLRTNNSSTIVVPYINCTPMDSMLRHNNVSLVIIPICPLRTPSGAPTTLPITVSIAPDRSEFSGARQSATRQ

[0069] [SEQ ID No:7]

[0070] Therefore, preferably, the RV-C07 VP0 peptide comprises an amino acid sequence substantially as set forth in SEQ ID No: 7, or a variant or fragment thereof.

[0071] The VP4 peptide of RV-C07 constitutes amino acid residues 1-67 of SEQ ID No: 7, and the VP2 peptide of RV-C07 constitutes amino acid residues 68-330 of SEQ ID No: 7. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-C07 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0072] In one embodiment, the RV-C07 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 8, as follows:

[0073] ATGGGCGCTCAGGTTTCCAAGCAGAGTGTGGGAGCTCATGAAACTATGGTGCATGCTGGCTCTGGTGCAGTTGTTAAATACTTCAACATCAATTATTACAAGGATGCTGCTAGCTCCGGTTTGACCAAACAAGATTTCTCACAAGACCCATCCAAGTTTACTCAGCCTGTAGCAGATTTACTGACAAATCCAGCTTTGATGTCCCCATCAGTTGAGGCGTGTGGATACTCCGATAGGCTCAAGCAAATCACTATCGGAAGCTCCACCATTACAACACAAGATTCTGTCAACACCATAGTTGCCTATGGCGAGTGGCCTAGTTATTTGTCAGATTTAGATGCATCATCTGTTGATAAACCCACACATCCTGAAACATCGGCTGACAGATTCTACACTTTGGACAGCGTACGCTGGGGTGGTAGTTCCAAAGGATGGTGGTGGAAGTTGCCAGACTGTTTGAAGAACATGGGTATATTTGGGCAGAACATGTACTACCACGCTATGGGAAGGTCTGGTTACATCATACACACCCAGTGCAATGCCACTAAGTTCCACAGTGGATGTCTGTTGGTAGCGGTTGTTCCCGAACACCAGCTAGCTTACATTGGGGGTACCAATGCACAAGTTAGCTACAAACATACTCACCCAGGTGAACGTGGGCATGAAATAGGTCTCAACACAAGCAGAGGTGACAACCGGCCAGATGAGGATCCCTTTTTTAATTGCAACGGAACACTATTAGGTAACTTGACTATTTTCCCTCACCAGCTCATAAACCTGAGGACAAATAACTCCAGCACCATAGTTGTGCCTTACATTAACTGCACACCAATGGACAGTATGTTACGCCACAACAATGTCTCTCTTGTAATTATACCCATCTGTCCTTTACGAACTCCCAGTGGAGCACCCACTACCTTACCAATTACTGTTTCAATTGCCCCAGACAGATCTGAATTCTCTGGCGCCAGGCAGTCCGCCACCCGCCAG

[0074] [SEQ ID No:8]

[0075] Thus, preferably, the RV-C07 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 8 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 8 or a variant or fragment thereof.

[0076] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 8 is provided herein as SEQ ID No: 9, as follows:

[0077] AUGGGCGCUCAGGGUUCCAAGCAGAGUGUGGUCGCUCUGGUGCAGUUGUAAAAUAUCUUCAACAUCAAUUAUUACAAGGAUGCUGCUCCGGUUUGACCAAACAAGAUUUUCUCACCAAGACCCAUCCAAGUUUACUCAGCCUGUAGCAGAUUUACUGACAAAUCCAGCUUUGAUCCCAAUCAUGGUUGGAUACUCCGAUAGGCUCACCAAAGUAUCGUCAAAUCUAUCGGAAGCUCCACCAUAUACAACACAAGAUUCUGCUCAACACAAGAUUCUGCUCAAGUAUUUGUCCAGUGUCUCAAGUUAUUGUCCAGUAUUUUGUCAGAUAUUAAGAUGCCACUUGUAAACCCACACUUCCUGAAACAUCGGCUGACAGAUUCUAACCUUAUUCUAACCUUUGGACAGCGUACGGGUGGUGAAGUUCCAAAGGAUGGUUGGUGAAGUUGCCCAGACUUUGAGAAACCUUGGUAUAUUUGGGCACAACAUUGUACUAC CACGCUAUGGGAAGGUCUGGUUACAUCAUACACACCCAGUGCAAUGCCACAUAGGUCCACAGUGGAUGUCUGUUGGUAGCGGUUGUGUCGUUCCGAAACCACCAGCUUACAUUGGGGUACCAAUGCACAAGUUAGCUACAAACAUACAUACUCACCCAGGUGAACGUGGCAUGAAAUAGGUCUCAACACAAGCAGGUGACAACCGGCCAGAUGAGGAUCCCUUUUUAAUUGCAACGGAACAUUAGUACUUGACUUUUUCCUCACCAGCUAUAAACCUGAGGACAAAUAUACCUCAGCCAGCAUAUUGUGUGCCUUAACAUAUACCUACUUAACCUUACUAGCACAAUGUUGUCCUCUUGUAAUUAACCCAUCUUGUCCUUUUACGAACUCCACAGUGGAGCCACUACUUACUACCUACUUACCCACUUGGAGCCACUACUUACUACUUACUACUUCUCUCUUGUAAUUACCCACUUGUCCUUUUACGAACUCCACAGUGGAGCCACUACUUACUACUUCUCUUUUACCCACGACAUUACUCUUUU

[0078] [SEQ ID No:9]

[0079] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 9, or a variant or fragment thereof.

[0080] In one embodiment, the amino acid sequence of the RV-C19 VP0 peptide is provided herein as SEQ ID No: 10, as follows:

[0081] MGAQVSKQNVGSHENSVSASNGSVIKYFNINYYKDSASSGLTKQDFSQDPSKFTQPLVDTLTNPALMSPSVEACGFSDRLKQITIGNSTITTQDSLNTVLAYGEWPSYLSDLDATSVDKPSHPETSSDRFYTLESVDWKSGSKGWWWKFPDALKDMGMFGQNMYH HSMGRFGALIHVQCNATKFHSGCLLIMVVPEHQLAYIGAEGVKVRYEHTHPGEKGHTLKGSQDRSTNNPDDNPFYMCNGTLLGNGMLYPHQMINLRTNNSATIVIPYINCVPMDNMLRHNNFSLVIVPIVPLRPGNSGAPILPITVTIAPYKSEFSGAMKSQPNQ

[0082] [SEQ ID No:10]

[0083] Therefore, preferably, the RV-C19 VP0 peptide comprises an amino acid sequence substantially as set forth in SEQ ID No: 10, or a variant or fragment thereof.

[0084] The VP4 peptide of RV-C19 constitutes amino acid residues 1-67 of SEQ ID No: 10, and the VP2 peptide of RV-C19 constitutes amino acid residues 68-330 of SEQ ID No: 10. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-C19 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0085] In one embodiment, the RV-C19 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 11, as follows:

[0086] ATGGGTGCACAGGTCAGCAAACAGAATGTTGGATCACACGAAAACTCTGTGTCTGCTAGTAATGGCTCTGTAATCAAGTACTTTAACATCAATTACTATAAAGACTCTGCCAGCTCTGGGTTGACTAAACAAGACTTTTCACAAGACCCGTCCAAATTTACTCAACCACTCGTTGACACACTGACAAATCCCGCCTTGATGTCCCCAAGTGTTGAAGCTTGTGGGTTTTCCGATAGGCTTAAACAAATCACTATCGGAAACTCCACTATTACAACACAAGATTCGCTCAACACCGTCTTGGCGTATGGAGAATGGCCTTCATACCTCTCTGACCTAGATGCCACCTCAGTAGATAAACCATCACACCCAGAAACCTCCTCAGACCGATTCTATACACTAGAAAGTGTTGATTGGAAGTCCGGATCTAAAGGTTGGTGGTGGAAATTTCCAGATGCCCTAAAAGATATGGGAATGTTTGGGCAAAACATGTACCACCATTCAATGGGTAGGTTTGGAGCTCTCATACATGTCCAATGTAATGCTACTAAATTTCACAGTGGTTGTCTCCTGATCATGGTTGTCCCCGAACATCAATTAGCATATATAGGGGCAGAAGGTGTCAAGGTTAGATATGAGCACACACACCCAGGAGAAAAGGGCCATACCTTGAAAGGTAGCCAGGATAGATCAACTAACAATCCAGATGATAACCCATTCTACATGTGTAACGGTACACTACTGGGTAATGGTATGTTATATCCTCATCAGATGATCAACCTCCGCACCAACAACTCAGCCACTATTGTAATTCCATACATCAACTGTGTACCCATGGACAATATGTTGCGCCACAACAACTTCAGTCTGGTGATTGTACCAATAGTACCCTTGAGACCTGGGAACTCAGGAGCTCCTATCTTACCCATCACTGTGACCATAGCACCATACAAATCAGAGTTTTCTGGAGCTATGAAATCCCAACCCAATCAG

[0087] [SEQ ID No:11]

[0088] Thus, preferably, the RV-C19 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 11 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 11 or a variant or fragment thereof.

[0089] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 11 is provided herein as SEQ ID No: 12, as follows:

[0090] AUGGGUGCACAGGUCAGCAAACAGAAUGUUGGAUCACACGAAAACUCUGUGUCUGCUAGUAAUGGCUCUGUAAUCAAGUACUUUAACAUCAAUUACUAUAAUAAAGCUCUGCCAGCCUCUGGGUUGACUAAACAAGACUUUUCACAAGACUUUCACAAGACCCGUCCAAAUUUACUCAACCACUGGUUGACCACACUGACAAAUUCCCGCCUUGUGUCCCCAAGUGUUGAAGCUUGGGGUUUUCCGAUAUAGGCUUAAACAAAUCACUAUCGGAACUCCACUAUUACAACACAAGAUUCGCUCUUGGCCUUCUGACCUAGAUUGCCACCUCAGUAGAUAAACCUACACCACAGAAACCUCCUCAGACCGAUUCUAUAUACACCUAGACCGAUUCUAUACACUAGAAAGGUUGUGGUGGUAAAUUCCAUGAUUCCCGAAUCUUAAUAUUGGGUAUGGAAUAUAUUCCAGAUGUAAUUGGUUGGUGGUAAAUUCCAUGCCCUAAAGUAUGGGUAUGGUUGGAAAUUUCCAGAUGCCCUAAAGUAUGGGUAUGGUUGGUGGUAAAUUUCCAGAUGCCCUAAAGUAUGGGUAUGGUUGGCAAAAUUGUGGCAAAACAUUGGAACCCACAGAAUGGUUGGUUGGAAAUUUCCAGAUGCCCUAAAGUAUGGGUAUGGUUGGUUGGAAAUUUCCAGAUGCCCUAAAGUAUGGGUAUGGUUGGCAAAAUUGUGGCAAAACAUUGGAACCC AUUCAAUGGGUAGGUUUGGAGCUCUCAUACAUGCCAAUGUAUGCUACUAAAUUUCACAGUGGUGUCUCCUGAUCAUGGUUGUCCCCGAACAUCAAUUAGCAUAUAUAGGGGCAGAAGGUGUCAAGGUUAGAAUAGGCACACACACCCAGGAAAAGGGCCAUACCUUGAAAGGUAGCCAGGGAUAGAUCAACUAACAAUCCAGAAUGAUAACCCAUUCUAACAUGUGUAACGGUACACUAGGU AAUGGUAUGUUAUAUUCCUCAUCAGAUGAUCAACCUCCGCACCAACAACUCAGCCACUAUUGUAAUUCCCAUACAUCAACUGUGUACCCAUGGACAAUAUGUUGCGCCCAACAACUUCAGUCUGUGAUGUACCAAUAGUACCCUUGAGACCUGGGAACUCAGGAGCUCCUAUUCUACCCAUCACUGUGACCACUAGCACCAUACAAAUCAGAGUUUUCUGGAGCUAUGAAAUCCCAACCCAAUUAACAG

[0091] [SEQ ID No:12]

[0092] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 12, or a variant or fragment thereof.

[0093] In one embodiment, the amino acid sequence of the RV-C24 VP0 peptide is provided herein as SEQ ID No: 13, as follows:

[0094] MGAQVSKQNVGSHENSVSATGGSVIKYFNINYYKDSASSGLTKQDFSQDPSKFTQPLAEALTNPALMSPTVEACGMSDRLKQITIGNSTITTQDTLNSILAYGEWPKYLSDLDASSVDKPTHPETSSDRFYTLTSVDWTTTSKGWWWKLPDCLKDMGIFGQNLY HHALGRSGYIIHTQCNATKFNSGCLIVAVVPEHQLAYIGEANVNVGYDHTHPGEGGHVIGSNVRRDNKQPDEDPFFNCNGTLLGNITIFPHQLINLRTNNSSTIVVPYINCVPMDNMLRHNNLSLVIIPIVPLRAANGVTKVPITISIAPDKSEFSGARQSVKQ

[0095] [SEQ ID No:13]

[0096] Therefore, preferably, the RV-C24 VP0 peptide comprises an amino acid sequence substantially as set forth in SEQ ID No: 13, or a variant or fragment thereof.

[0097] The VP4 peptide of RV-C24 constitutes amino acid residues 1-67 of SEQ ID No: 13, and the VP2 peptide of RV-C24 constitutes amino acid residues 68-328 of SEQ ID No: 13. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-C24 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0098] In one embodiment, the RV-C24 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 14, as follows:

[0099] ATGGGCGCACAGGTCAGCAAGCAAAATGTCGGCTCGCATGAAAACTCAGTCTCAGCCACAGGTGGATCCGTGATTAAGTATTTCAACATCAATTACTACAAGGATTCTGCTAGCTCTGGCTTGACTAAACAAGATTTTTCCCAAGACCCATCGAAATTCACACAACCTCTAGCAGAAGCACTTACAAATCCAGCTTTAATGTCACCAACTGTTGAAGCATGTGGGATGTCCGATAGGCTTAAACAAATTACTATCGGGAATTCCACTATAACAACACAAGATACACTAAACTCTATACTGGCATATGGGGAGTGGCCCAAATACTTGAGTGACCTGGACGCTTCCTCAGTGGATAAACCTACCCACCCAGAAACATCATCTGATAGATTTTACACATTAACTAGTGTAGATTGGACCACTACGTCTAAAGGTTGGTGGTGGAAGTTGCCTGATTGCCTTAAAGATATGGGCATCTTCGGGCAAAATCTGTACCATCATGCATTGGGTAGGTCAGGGTACATAATACACACCCAATGTAATGCCACAAAATTCAATAGTGGTTGTCTAATAGTGGCTGTTGTACCAGAACACCAGCTAGCTTACATAGGTGAAGCAAATGTCAATGTTGGTTATGATCACACACACCCTGGTGAGGGAGGACATGTAATTGGTTCAAATGTTAGGAGAGATAACAAGCAACCTGATGAAGACCCCTTCTTTAATTGTAATGGGACCCTGCTTGGTAACATCACTATATTCCCACACCAGCTCATAAACTTGAGGACAAACAATTCCAGCACAATTGTTGTACCATACATTAATTGTGTACCTATGGACAACATGCTCAGGCACAACAACCTATCTCTAGTTATTATTCCAATCGTTCCTCTCAGAGCCGCAAATGGTGTCACCAAGGTCCCCATTACAATCTCAATAGCACCAGATAAGTCAGAGTTCTCAGGGGCTAGACAGTCTGTAAAACAG

[0100] [SEQ ID No:14]

[0101] Thus, preferably, the RV-C24 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 14 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 14 or a variant or fragment thereof.

[0102] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 14 is provided herein as SEQ ID No: 15, as follows:

[0103] AUGGGCGCACAGGUCAGCAAGCAAAUUGCGGCUCGCAUGAAAACUCAGCUCAGCCAGGUGGAUCCGUGAUUAAGUAUUUUCACAUCAAUUACUACAAGGAUUCUGCUGGCUUGACUAAACAAGAUUUUUCCCAAGACCAUCGAAAUUCACACCUCUUAGGCAGAAGCACUUACAAAUUCCAGCUUACAAAUUCAGCUUUAAUAUUCCACCAAGUUGGAAGCAUGUGGGAUGCCUUAAGCUUAAACAAAUUCGGGAAUUCCACUUAAACAACAACACAAGAUACACUUAAUCUCUAUACUGGCAUUGGGAGUGCCCAAAUAUCUUGAGUGGACGCUUCCUCAGUGAUAAAACCUACCCACCAGAAACAUCAUUGUGGAUUUUACACAUUAUACUAUGUGUAGAUUGGACCCUACGUCUCUCUUAAAAGGUUGGUGGUGGAAGGUUGGCCUUGAUUGCCUUAAAAGAUAGGUGGCAUCUUCGGGCAAAAAUCUCUGUAC AUCAUGCAUUGGUUAGGUAGCAGGGUACAUAAUACACACCAAUGUAAUGCCACAAAAUAUAUUGGUUGUCUAAUAUAGUGGUUGCUGUUGUUCCAGAACACCAGCUUAACAUAGGUGAAGCAAAUUGCAAAUUGGUUGGUUAAUUGGUUAAUUGGUUAAUAGGAGAUAAACAAGCAACCUGAUGAAGACCCCUUCUUUAAUUGUAAUUGGUAAAUUGGUAAAUUGGUACCCUCUGGUUAACAUAUAUUCCACACCAGCUCUAUAUAUAGGACAAACAAUAUUCCAGCACAAUUGUGUGUACCAUAUAUAUUGGUACCUAUAUUGUACCAUAUAUAUUGUACCAUAUAUAUUCCAAUUCCUCUCAGAGCCGCAAAUUGGUUCACCAAGGUCCCCAUUAAUAUAUCUCAAUAUAGCACCAGUAAUAGCACAGUAUAUGUCAGAGGUUCUGUAAAACAGCAGCA

[0104] [SEQ ID No:15]

[0105] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 15, or a variant or fragment thereof.

[0106] In one embodiment, the amino acid sequence of the RV-C01 VP0 peptide is provided herein as SEQ ID No: 16, as follows:

[0107] MGAQVSRQSVGSHETMIHAGTGAVVKYFNVNYYKDAASSGLTKQDFSQDPSKFTQPVADILTNPALMSPSVEACGFSDRLKQITIGNSTITTQDAVNTIVAYGEWPSYLSDLDATSVDKPTHPETSSDRFYTLRSVDWRGGSKGWWWKLPDCLKDMGIFGQNMF HHAMGRSGYIIHTQCNATKFHSGCLLVAVVPEHQLAYIGADARVSYEHTHPGERGHTIGSNADRNNHQPDENPFFNCNGTLLGNLTIFPHQLINLRTNNSSTIVVPYINCTPMDSMLRHNNVSLVIIPICPLRPPTTGQQVLPITISIAPIKSEFSGARQAIKQ

[0108] [SEQ ID No:16]

[0109] Therefore, preferably, the RV-C01 VP0 peptide comprises an amino acid sequence substantially as set forth in SEQ ID No: 16, or a variant or fragment thereof.

[0110] The VP4 peptide of RV-C01 constitutes amino acid residues 1-67 of SEQ ID No: 16, and the VP2 peptide of RV-C01 constitutes amino acid residues 68-328 of SEQ ID No: 16. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-C01 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0111] In one embodiment, the RV-C01 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 17, as follows:

[0112] ATGGGCGCACAGGTGTCTAGACAGAGTGTCGGGAGCCATGAAACCATGATCCATGCTGGGACTGGAGCCGTAGTAAAGTACTTCAATGTCAATTATTACAAAGATGCAGCAAGCTCTGGATTGACCAAGCAAGATTTCTCCCAGGATCCATCCAAATTTACTCAACCCGTGGCCGACATCCTGACCAACCCAGCTTTGATGTCCCCCTCCGTTGAAGCTTGTGGGTTTTCCGATAGGCTCAAGCAAATCACTATTGGAAACTCCACTATAACAACCCAAGATGCAGTCAATACAATTGTGGCATACGGGGAATGGCCCAGTTATCTATCAGATTTGGATGCGACTTCAGTTGATAAACCGACGCACCCTGAGACATCATCAGACAGATTTTACACGCTGAGGAGTGTTGACTGGCGAGGTGGTTCAAAAGGGTGGTGGTGGAAACTGCCTGATTGTCTGAAAGACATGGGAATATTTGGGCAAAACATGTTCCACCATGCCATGGGAAGATCAGGATACATCATACACACCCAGTGCAATGCAACTAAATTTCACAGTGGATGTTTACTCGTGGCAGTAGTGCCTGAACACCAATTAGCATACATAGGTGCAGATGCACGAGTGAGTTATGAGCACACCCACCCTGGTGAGCGAGGCCATACAATTGGTAGCAACGCAGACAGGAATAACCATCAGCCAGATGAAAATCCTTTCTTCAACTGTAACGGGACTTTACTTGGAAATTTGACTATCTTCCCACACCAGCTTATAAATTTAAGGACAAACAACTCAAGCACCATCGTCGTGCCTTACATCAATTGCACTCCTATGGATAGCATGTTACGGCACAACAATGTATCACTTGTTATCATACCCATTTGCCCTTTACGGCCCCCAACCACAGGGCAGCAAGTCTTACCGATCACCATTTCTATTGCTCCCATAAAATCAGAGTTTTCAGGGGCTAGGCAGGCCATTAAACAA

[0113] [SEQ ID No:17]

[0114] Thus, preferably, the RV-C01 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 17 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 17 or a variant or fragment thereof.

[0115] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 17 is provided herein as SEQ ID No: 18, as follows:

[0116] AUGGGCGCACAGGUGUCUAGACAGAGUGUCGGGAGCCAUGAAACCAUGAUCCAUGCUGGAGCCGUAGUAAGUACUUCAAUGUACUUAUAUUACAAAGAUGCAGCAAGCUCUGGAUUGACCAAGCAAGAUUUCUCCCAGGAUCCAUCCAAAUUUACUCAACCGUGGCCGACAUCCUGACCAACCCAGCUUUGAUUGUCCCCUCCGUUGAAGCUUGUGGUUUUCCGAUAGGCUCAAGCAAAUAUUGGAAACUCCAAUAACAACCCAAGAUGCAGUCAUAACAAUUGUGGCAUUACGGGGAAUGGCCCAGUUAUCUAUCAUCAGAUUUGGAUGCGACUUCAGUUGUAAAACCCGAGCCACCCUGAGACAUCAUUUUACACGCUGAGGAGUGUUGACUGCGGAGGUGGUUCAAAAAGGGUGGUGGUGGAAAACUGCCCUGAUUGUGGAAAACUGCCCUGAAUUGUGGAAAAGCAUGGGGAAUAUUUGGGCAAAACAUGUUC CACCAUGCCAUGGGAAGAUCAGGAUACAUCAUCACACACCACCAGUGCAUUGCAACUAAAUUUCACAGUGGAUGUUUACUCGUGGCGUAGUGCCUGUAACCAAUUAGCAUAUAGCAUACGCAGUGAGUUAUGAGCACCACCCUGUGUGGCGAUGCCAUACAAUUGGUGAGCAACGCAGACAUGGAAUACCAUCAGCCAGCAUGUAAAUCCUUUCUUCAACUGUACGGACUUUAUGUAGCAAAUAUCUUCCACACCAGCUAUAUAUAUAUAUAGGACAAACAACUCAAGCACCAUCGUCGUGCCUUACAUCAAUUGCACUUCCUAUAUAUAUAUAUAUAGGACAAUGUACGCACAAUGUACGCACAAUGUACGCACAAUGUACGCACAAUGUACGCACAAUGUACGCACAAUGUACGCACAAUGUACGCACAAUGUACGCACAAGUCUUACCGAUCCAAUUGUCCUUUACCCAACCGCCACACAGGGCAGCAAGUCUUACCGAUCACCAUUUUUCCUUCCAUAAAAUCAGAGUUUUCCAUAAAUCAGGUUUCCAGGCAGGCAGGCAGCCAUUAAACAA

[0117] [SEQ ID No:18]

[0118] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 18, or a variant or fragment thereof.

[0119] In one embodiment, the amino acid sequence of the RV-A28 VP0 peptide is provided herein as SEQ ID No: 19, as follows:

[0120] MGAQVSRQNVGTHTTQNAVSNGSSLNYFNINYFKDAASSGASRLDFSQDPSKFTDPVKDVLTKGIPTLQSPSVEACGYSDRIIQITRGNSTITSQDIANAVVAYGVWPEYLPSQDASAIDKPTHPDTSSNRFYTLESKNWTATSKGWWWKLPDALKNMGIFGENLF YHFLGRAGYTVHVQCNASKFHQGTLIVAAIPEHQLAFISKGNVTVGYNYTHPGEQGREIGTFGPSSTLDRQPSDENWLNCDGTLLGNITVYPHQYINLRSNNSATLILPYVNAVPMDSMVRHNNWSIVIIPISKLETEGGTTIVPITLSISPMFSEFSGARNNVPQ

[0121] [SEQ ID No: 19]

[0122] Therefore, preferably, the RV-A28 VP0 peptide comprises an amino acid sequence substantially as set forth in SEQ ID No: 19, or a variant or fragment thereof.

[0123] The VP4 peptide of RV-A28 constitutes amino acid residues 1-69 of SEQ ID No: 19, and the VP2 peptide of RV-A28 constitutes amino acid residues 70-332 of SEQ ID No: 19. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-A28 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0124] In one embodiment, the RV-A28 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 20, as follows:

[0125] ATGGGCGCTCAAGTATCTAGGCAGAATGTTGGCACACACACCACACAAAATGCTGTATCAAATGGCTCTAGTTTGAATTATTTTAACATCAACTACTTTAAAGATGCTGCCTCAAGTGGAGCATCACGACTAGATTTTTCACAAGATCCTAGTAAATTCACTGATCCAGTTAAAGATGTTCTTACAAAAGGTATACCAACTCTACAATCACCCAGTGTTGAGGCATGTGGTTATTCAGATAGGATCATACAAATAACACGAGGGAATTCAACAATTACTTCACAAGATATAGCAAATGCTGTAGTAGCCTATGGAGTTTGGCCTGAATATCTGCCTAGTCAAGATGCTAGTGCAATAGACAAACCAACACATCCTGACACCTCTTCTAACAGATTCTATACATTGGAAAGCAAAAATTGGACTGCAACCTCAAAAGGATGGTGGTGGAAACTTCCAGATGCTCTCAAGAATATGGGGATCTTTGGTGAGAATCTTTTCTATCATTTCCTTGGTAGAGCCGGGTACACTGTACATGTGCAGTGTAATGCTAGCAAGTTTCACCAGGGTACCCTAATAGTTGCTGCCATTCCAGAACATCAGTTGGCTTTCATTTCCAAGGGTAATGTCACAGTTGGTTATAATTATACACACCCTGGTGAACAAGGCCGTGAAATAGGCACCTTTGGACCCAGTAGCACATTGGACAGACAACCTAGTGATGAAAATTGGCTTAATTGTGATGGCACACTTTTGGGAAATATAACAGTGTATCCACACCAATATATCAACCTCAGAAGTAACAATTCAGCAACATTAATATTACCATATGTTAACGCCGTACCCATGGACTCTATGGTTAGGCATAACAATTGGAGTATAGTGATTATACCCATATCTAAATTAGAGACTGAGGGTGGGACAACAATTGTACCCATAACTTTATCTATTAGCCCAATGTTTTCAGAGTTTTCTGGGGCGAGAAACAATGTCCCTCAA

[0126] [SEQ ID No:20]

[0127] Thus, preferably, the RV-A28 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 20 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 20 or a variant or fragment thereof.

[0128] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 20 is provided herein as SEQ ID No: 21, as follows:

[0129] AUGGGCGCUCAAGUAUCUAGGCAGAAUGUUGGCACACACACCACAAAAUGCUGUAUCAAAUGGCUCUUAGUUGGACUACCACUAGAUUUUUAACAUCAACUACUUUUUUCACAAGAUCCUAGUAAAUAUUCACUGUAUCCAGUUAAAGAUGUUCUUACAAAAGGUAUACCAACUCUACAAUCACCAGUGUUGUGGUUAUUCACAGUAUAAGGAUCAUACAAAUAACACGAGGGAAUUCAACAAUUACUACUUCACCAAAGAUAUAGCAAAUAGCUAGCUAGCUAUUGGAUCCUAUUGGCCUGAAUAUUCUGCCUAGUAUAUUCUGCCUAGUCAGUAUAGCUAGCUAGCUAGUAUGCUAGCAAUGGCAAAUAUACACCUGACACUUCUAACAGAUUCUAAUACAUUGGAAAGCCAAAAAUGGGUGGUGGAAACUUCCAGAUGCUCUCAAGAAUAUGGGGAUCUUGGUGAAUCUUUC UAUCAUUUCCUUGGUAGAGCCGGUACACUGUACUGUGCAGUGUAUAGCUAGCAAGUUUCACCAGGGUACCCUAAUAGUUGCUGCCAUUCCAGAACAUCAGUUGGCUUUCAUUUCCAAGGGUAUUGCUCACAGUUGGUUAAUAUAUAUAUACACACCCUGGUGAACAAGGCCGUGAAAAUAGGCACCUUUUGGACCCAGUAGCACAAUUGGACACACUUACUUGGUUAAUUGGCUUAAUUGUGGACACACUUUUGGAAAAUAUAUAUAACAGUGUAUCCACCAAUAUAUAUAUACCUACCUCAUGUAGUAACAAUUCAGCAACCUAUAUAUAUAUACCAUAUAUAUACCAUAUAUAUAGGAGACUGACUCUAUUGGUUAGCCAUAACUAUAUAUAUAUAGGACACUGAGGGUGGCAAAUUGUACCCAUAACUUUAUAUCUAUUACUAUUAUCCAAUUUACUAUUACUAUUAUCCAAUUUACUAUUACUAUUAGCCCAAUUUUACUAUUACUAUUAUC

[0130] [SEQ ID No:21]

[0131] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 21, or a variant or fragment thereof.

[0132] In one embodiment, the amino acid sequence of the RV-A29 VP0 peptide is provided herein as SEQ ID No: 22, as follows:

[0133] MGAQVSRQNVGTHSTQNSVSNGSSLNYFNINYFKDAASSGASKLEFSQDPSKFTDPVKDVLEKGIPTLQSPTVEACGYSDRIMQITRGDSTITSQDVANAVIGYGVWPHYLSAEDATAAIDKPTQPDTSSNRFYTLESKTWNRQSKGWWWKLPDALKDMGIFGENMYY HYLGRSGYTVHVQCNASKFHQGTLLVVMIPEHQLASVGTDKVGPGYAFTHPGEAGRQIGNVSEPTSKHPSDDNWLNFDGTLLGNVLIFPHQFINLRSNNSATIIVPYVNAVPMDSMLRHNNWSLVIIPISELQAENATNVTVPITVSISPMFAEFSGARARPARATTQ

[0134] [SEQ ID No:22]

[0135] Therefore, preferably, the RV-A29 VP0 peptide comprises an amino acid sequence substantially as set out in SEQ ID No: 22, or a variant or fragment thereof.

[0136] The VP4 peptide of RV-A29 constitutes amino acid residues 1-69 of SEQ ID No: 22, and the VP2 peptide of RV-A29 constitutes amino acid residues 70-335 of SEQ ID No: 22. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-A29 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0137] In one embodiment, the RV-A29 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 23, as follows:

[0138]

[0139] [SEQ ID No:23]

[0140] Thus, preferably, the RV-A29 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 23 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 23 or a variant or fragment thereof.

[0141] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 23 is provided herein as SEQ ID No: 24, as follows:

[0142]

[0143] [SEQ ID No:24]

[0144] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 24, or a variant or fragment thereof.

[0145] In one embodiment, the amino acid sequence of the RV-A89 VP0 peptide is provided herein as SEQ ID No: 25, as follows:

[0146] MGAQVSRQNVGTHSTQNSVSNGSSLNYFNINYFKDAASSGASRLDFSQDPSKFTDPVKDVLEKGIPTLQSPTVEACGYSDRLIQITRGDSTITSQDIANAVVAYGVWPSYLTPDDATAIDKPTQPDTSSNRFYTLDSRSWTSASSGWWWKLPDALKNMGIFGENMFYH FLGRSGYTIHVQCNSSKFHQGLLIVAAIPEHQLASATSGNVSVGYNHTHPGEQGREVVPSRTSSDNKRPSDDSWLNFDGTLLGNLPIYPHQYINLRTNNSATLILPYVNAVPMDSMLRHNNWSLVIIPICPLQVQPGGTQSIPITVSISPMFSEFSGPRNKVVFSTTQ

[0147] [SEQ ID No:25]

[0148] Therefore, preferably, the RV-A89 VP0 peptide comprises an amino acid sequence substantially as set out in SEQ ID No: 25, or a variant or fragment thereof.

[0149] The VP4 peptide of RV-A89 constitutes amino acid residues 1-69 of SEQ ID No: 25, and the VP2 peptide of RV-A89 constitutes amino acid residues 70-336 of SEQ ID No: 25. Thus, in embodiments where the immunogenic composition comprises a fragment of RV-A89 VP0, the fragment may comprise or consist of amino acids forming the VP2 and / or VP4 peptides.

[0150] In one embodiment, the RV-A89 VP0 peptide is encoded by the nucleotide sequence (DNA) of SEQ ID No: 26, as follows:

[0151]

[0152] [SEQ ID No:26]

[0153] Thus, preferably, the RV-A89 VP0 peptide is encoded by a nucleotide sequence substantially as set forth in SEQ ID No: 26 or a variant or fragment thereof. Alternatively, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence substantially as set forth in SEQ ID No: 26 or a variant or fragment thereof.

[0154] In one embodiment, the RNA sequence corresponding to the DNA sequence of SEQ ID No: 26 is provided herein as SEQ ID No: 27, as follows:

[0155]

[0156] [SEQ ID No:27]

[0157] Thus, in one embodiment, the immunogenic composition comprises an isolated polynucleotide comprising a nucleotide sequence (RNA) substantially as set forth in SEQ ID No: 27, or a variant or fragment thereof.

[0158] As used throughout, the term "immunogenic composition" refers to a composition of matter (intended for administration to a subject) that includes at least one antigen or induces expression of at least one antigen of a rhinovirus (in the case of nucleic acid immunization) that has the ability to elicit an immune response in the subject to which it is administered. Such an immune response may be a cellular and / or antibody-mediated immune response to at least the antigens of the composition.

[0159] The immunogenic compositions described herein provide an effective method of vaccinating a subject against RV infection. Thus, in a preferred embodiment, the immunogenic composition is a vaccine.

[0160] The immunogenic composition may include a suitable adjuvant. In a preferred embodiment, the adjuvant is a Th1 adjuvant. Examples of Th1 adjuvants that promote a Th1 immune response include TLR-9 agonists, such as CpG oligonucleotides, or TLR-4 agonists. Alternatively, in another embodiment, the adjuvant is incomplete Freund's adjuvant (IFA).

[0161] Further examples of adjuvants may include aluminum salts, synthetic forms of DNA, carbohydrates, tablet binders, ion exchange resins, preservatives, polymers, emulsions and / or lipids. Examples of adjuvants may include sodium glutamate, sucrose, dextrose, bovine aluminum, human serum albumin, cytosine phosphate guanine, potassium phosphate, Plasdone C, anhydrous lactose, cellulose, polacrilin potassium, glycerol, asparagine, citric acid, potassium phosphate, magnesium sulfate, ammonium ferric citrate, 2-phenoxyethanol, aluminum, β-propiolactone, bovine extract, DOPC, EDTA, formaldehyde, thimerosal, phenol, potassium aluminum sulfate, potassium glutamate, sodium borate, sodium metabisulfite, urea, PLGA, PVA, PLA, PVP, cyclodextrin-based stabilizers, oil-in-water emulsion adjuvants and / or lipid-based adjuvants.

[0162] The immunogenic composition according to the first aspect is particularly suitable for use in the treatment or prevention (ie vaccination) of rhinovirus infection.

[0163] Thus, in a second aspect of the invention there is provided an immunogenic composition according to the first aspect for use in treatment or prevention.

[0164] In a third aspect, there is provided an immunogenic composition according to the first aspect for use in eliciting an immune response.

[0165] In a fourth aspect, there is provided a method of eliciting an immune response in a subject, the method comprising administering to a subject in need of an immune response a therapeutically effective amount of the immunogenic composition according to the first aspect.

[0166] It will be understood that the uses and methods of the invention include vaccination.

[0167] In a preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against rhinovirus infection.

[0168] Preferably, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against at least one, at least two or at least three rhinoviruses, more particularly against RV-A, RV-B and / or RV-C.

[0169] Advantageously, the immune response elicited by the immunogenic composition according to the first aspect is a specific cell-mediated immune response, which is directed not only against the homologous strain of rhinovirus from which the immunogenic composition was derived, but also against other (heterologous) rhinovirus strains of the same species of rhinovirus, which other rhinovirus strains may extend to rhinovirus strains of another rhinovirus group.

[0170] Thus, preferably, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against at least one RV-A strain selected from the group consisting of RV-1A, RV-A1, RV-A10, RV-A100, RV-A101, RV-A103, RV-A106, RV-A107, RV-A108, RV-A11, RV-A12, RV-A13, RV-A14, RV-A15, RV-A16, RV-A17, RV-A18, RV-A19, RV-A20, RV-A21, RV-A22, RV-A23, RV-A24, RV-A25, RV-A26, RV-A27, RV-A28, RV-A29, RV-A30, RV-A31, RV-A32 -A13, RV-A15, RV-A16, RV-A18, RV-A19, RV-A1B, RV-A2, RV-A20, RV-A21, RV-A22, RV-A23, RV-A24 , RV-A25, RV-A28, RV-A29, RV-A30, RV-A31, RV-A32, RV-A33, RV-A34, RV-A36, RV-A38, RV-A39, RV- A40, RV-A41, RV-A43, RV-A44, RV-A45, RV-A46, RV-A47, RV-A49, RV-A50, RV-A51, RV-A53, RV-A54 , RV-A55, RV-A56, RV-A57, RV-A58, RV-A59, RV-A60, RV-A61, RV-A62, RV-A63, RV-A64, RV-A65, RV- In a preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against all RV-A strains.

[0171] Preferably, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against at least one RV-B strain selected from the group consisting of RV-B103, RV-B102, RV-B101, RV-B100, RV-B27, RV-B26, RV-B4, RV-B97, RV-B35, RV-B84, RV-B93, RV-B92, RV-B91, RV-B17, RV-B5, RV-B42, RV-B6, RV-B37, RV-B48, RV-B69, RV-B52, RV-B72, RV-B3, RV-B14, RV-B99, RV-B86, RV-B83, RV-B79 and RV-B70. In a preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against all RV-B strains.

[0172] Preferably, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against at least one RV-C strain selected from the group consisting of RV-C58, RV-C50, RV-C48, RV-C46, RV-C13, RV-C51, RV-C55, RV-C56, RV-C45, RV-C44, RV-C41, RV-C4, RV-C38, RV-C34, RV-C33, RV-C31, RV-C30, RV-C29, RV-C27, RV-C26, RV-C24, RV-C23, R In a preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect elicits an immune response against all RV-C strains.

[0173] Furthermore, rhinoviruses are well known to be a major cause of the common cold, viral wheezing illnesses in early childhood, and acute exacerbations (exacerbations) of lung diseases such as asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and chronic fibrotic lung disease.

[0174] Therefore, in a preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect triggers an immune response against the common cold, viral-induced wheezing diseases, acute attacks of lung diseases such as asthma, asthma attacks, bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis and / or chronic fibrotic lung diseases.

[0175] As used herein, the expression "eliciting an immune response" may relate to inducing a specific cell-mediated immune response. This means that after administration of an immunogenic composition in a subject, a specific T lymphocyte response is generated. The two main cellular effectors of a specific T lymphocyte response are helper T cells and cytotoxic T lymphocytes (CTLs).

[0176] CD4+ "helper" T cells or helper T cells are immune response mediators and play an important role in establishing and maximizing the ability of adaptive immune responses. These cells can have direct cytotoxic activity to some extent, but they essentially "manage" immune responses by directing other cells involved in protecting the organism from pathogens. The activation of naive helper T cells causes them to release cytokines, which can affect the activity of many cell types that activate it, such as B lymphocytes, CTLs, and APCs (antigen presenting cells). Helper T cells require much milder activation stimulation than cytotoxic T cells. Helper T cells can provide additional signals that "help" activate cytotoxic cells. Two types of effector CD4+ helper T cell responses can be induced by professional APCs, called Th1 and Th2. The measurement of cytokines associated with Th1 or Th2 responses will give a measure of successful immunity. This can be achieved by specific ELISA or ELISPOT designed to measure Th1 cytokines or Th2 cytokines, such as IFN-γ, IL-2, etc., and Th2 cytokines such as IL-4, IL-5, IL-13, etc.

[0177] As used herein, the expression "helper T cell-mediated immune response" refers to an immune response in which CD4 + T cells or helper T cells are activated and secrete lymphokines to stimulate cell-mediated and antibody-mediated immune system branches. As known to the technician, helper T cell activation promotes lymphokine secretion, immunoglobulin isotype conversion, affinity maturation of antibody response, macrophage activation and / or the activity enhancement of natural killer and cytotoxic T cells. Lymphokines are proteins secreted by lymphocytes that affect self-activity and / or the activity of other cells. Lymphokines include but are not limited to interleukins and cytokines, such as IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 or IFN-γ.

[0178] It is well known to the skilled person that helper T cells differentiate into two major subtypes of cells, called Th1 and Th2 cells (also known as type 1 and type 2 helper T cells, respectively).

[0179] In addition, it is well known to the skilled person that Th1 cells mainly secrete IL-2 and IFN-γ. They can effectively kill macrophages and cytotoxic CD8 + The type 1 cytokine IFN-γ promotes cellular immune responses by increasing the proliferation of T cells. In addition, the type 1 cytokine IFN-γ increases the production of IL-12 by dendritic cells and macrophages, and through positive feedback, IL-12 stimulates the production of IFN-γ in helper T cells, thereby promoting the Th1 profile. IFN-γ also inhibits the production of cytokines such as IL-4, an important cytokine associated with type 2 responses, so it also plays a role in maintaining its own response.

[0180] In contrast, Th2 cells secrete primarily IL-4, IL-5, and IL-13 and promote humoral immune responses by stimulating B cell proliferation and inducing B cell antibody class switching. Type 2 responses further promote their own spectrum using two different cytokines. IL-4 acts on helper T cells to promote the production of Th2 cytokines (including itself), while IL-10 inhibits multiple cytokines, including IL-2 and IFN-γ in helper T cells, and IL-12 in dendritic cells and macrophages.

[0181] Preferably, the cell-mediated immune response induced by the immunogenic composition of the invention is primarily a Th1 cell-mediated immune response.In a preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect induces an immune response through the secretion of IFN-γ.

[0182] A key component of protective cellular immunity elicited by natural respiratory virus infection is tissue-resident memory T cells (T cells) in the airway mucosa and lungs. RM ) are formed. These T RM Therefore, in another preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect is used to rapidly expand and clear subsequent infections by tissue-resident memory T cells (T RM ) induces an immune response.

[0183] In another preferred embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect induces an immune response through the production of RV VPO-specific IgG antibodies.

[0184] Alternatively, in another embodiment, the immunogenic composition for use according to the third aspect or the method according to the fourth aspect induces a cytotoxic T cell immune response.

[0185] Cytotoxic T cells (also called Tc, killer T cells or cytotoxic T lymphocytes (CTL)) usually express the CD8 marker and are a subset of T cells that may also participate in T cell-mediated immune responses. They induce the death of cells infected with viruses (and other pathogens). These CTLs directly attack other cells that carry certain foreign or abnormal molecules on their surface. This cytotoxic capacity can be tested using an in vitro cytotoxicity assay (chromium release assay). Therefore, when antigen-loaded target cells are lysed by specific CTLs generated in vivo after vaccination or infection, the presence of such cytotoxic T cells can demonstrate the induction of specific cellular immunity.

[0186] Similar to helper T cells, CD8 + T cells consist of different subunits, similar to the Th1 / Th2 terminology, which are referred to as Tc1 and Tc2.

[0187] Tc1 immune responses involve specific CD8 IFN-γ production + T cells, which are activated, proliferate and produce IFN-γ under specific antigen stimulation. + The levels of T cells can be measured by ELISPOT and by measuring intracellular IFN-γ in these cells by flow cytometry.

[0188] Naive cytotoxic T cells are activated when there is a strong interaction between their T cell receptor (TCR) and a peptide-bound MHC class I molecule. This affinity, which depends on the type and orientation of the antigen / MHC complex, is what binds the CTL to the infected cell. Once activated, the CTL undergoes a process called clonal expansion, in which it acquires function and rapidly divides, producing an army of "armed" effector cells. The activated CTL will then travel throughout the body, searching for cells carrying this unique MHC class I+ peptide. This can be used to identify such CTLs in vitro by using peptide-MHC class I tetramers in flow cytometry assays.

[0189] When exposed to these infected cells, effector CTLs release perforin and granulysin, which are cytotoxins that form pores in the plasma membrane of target cells, allowing ions and water to flow into the infected cell and causing it to rupture or lyse. CTLs release granzymes, which are serine proteases that enter the cell through the pores to induce apoptosis (cell death). The release of these molecules by CTLs can be used as a measure of the successful induction of a cellular immune response following vaccination. This can be accomplished by enzyme-linked immunosorbent assays (ELISA) or enzyme-linked immunospot assays (ELISPOT), in which CTLs can be quantitatively measured. Since CTLs are also able to produce important cytokines such as IFN-γ, IFN-γ-producing CD8 cells can be quantitatively measured by ELISPOT and by measuring intracellular IFN-γ in these cells by flow cytometry.

[0190] It will be appreciated that the immunogenic composition according to the invention may be used in a medicament which may be used as a monotherapy (i.e. the immunogenic composition alone) for vaccination against RV infection. Alternatively, the immunogenic composition according to the invention may be used as an adjunct to or in combination with known therapies for the treatment, amelioration or prevention of RV infection.

[0191] The immunogenic composition of the present invention can be combined into a composition with a variety of different forms, depending on the mode of use of the composition. Therefore, for example, the composition can be a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micellar solution, transdermal patch, liposome suspension, polymer, emulsion, lipid nanoparticles (e.g., surface with or encapsulated with peptides, DNA or RNA) or any other suitable form that can be applied to a person or animal in need of vaccination. Lipid nanoparticles can include one or more components selected from the group consisting of the following items: cationic lipids (preferably ionizable); phosphatidylcholine; cholesterol; and polyethylene glycol (PEG) lipids. It will be understood that the drug carrier according to the present invention should be a carrier that is well tolerated by the subject of administration.

[0192] The medicaments comprising the immunogenic compositions of the invention can be used in a variety of ways. For example, oral administration may be desired, in which case the agent may be contained in a composition that can be taken orally, for example, in the form of a tablet, capsule, or liquid. The compositions comprising the agents of the invention and the medicament can be administered by inhalation (e.g., intranasally). The compositions can also be formulated for topical use. For example, a cream or ointment can be applied to the skin.

[0193] The immunogenic compositions of the present invention may also be incorporated into a sustained or delayed release device. For example, such a device may be inserted on or under the skin, and the drug may be released over a period of weeks or even months. The device may be located at least near the treatment site. Such a device may be particularly advantageous when long-term treatment with the immunogenic composition is desired and frequent dosing (e.g., at least daily injections) is typically required.

[0194] However, in a preferred embodiment, the medicament according to the present invention can be administered by injection into the bloodstream, muscle, skin or directly into the site in need of treatment. The injection can be intravenous (bolus or infusion) or subcutaneous (bolus or infusion), or intradermal (bolus or infusion), or intramuscular (bolus or infusion).

[0195] It will be appreciated that the amount of the immunogenic composition required is determined by its biological activity and bioavailability, which in turn depends on the mode of administration, the physicochemical properties of the immunogenic composition, and whether it is used as a monotherapy or in combination therapy. The frequency of administration will also be affected by the half-life of the active agent in the subject being treated. The optimal dose for administration can be determined by one skilled in the art and will vary with the specific immunogenic composition used, the strength of the composition, the mode of administration, and the type and progression of the viral infection. Additional factors depending on the specific subject being treated will result in the need to adjust the dose, including subject age, weight, sex, diet, and time of administration.

[0196] Typically, depending on the agent used, a daily dose of between 0.001 μg / kg body weight and 100 mg / kg body weight of the immunogenic composition of the present invention can be used for immunization. More preferably, the daily dose of the agent is between 1 μg / kg body weight and 100 mg / kg body weight, more preferably between 10 μg / kg and 10 mg / kg body weight, and most preferably between about 100 μg / kg and 10 mg / kg body weight.

[0197] The daily dose may be administered as a single dose (e.g., a single daily injection or inhaled nasal spray). Alternatively, the immunogenic composition may need to be administered twice or more in one day. For example, the immunogenic composition may be administered as an initial primer and a subsequent booster, or two boosters may be administered at intervals of one week or one month. Preferably, the immunogenic composition may be administered as an initial primer and a subsequent booster, with an interval of two to six weeks. Preferably, subsequent boosters may then be administered annually to susceptible patients (e.g., patients with a weakened immune system). Known procedures, such as those commonly used in the pharmaceutical industry (e.g., in vivo experiments, clinical trials, etc.), can be used to form specific formulations and precise treatment regimens (e.g., daily doses and frequency of administration of agents) according to the immunogenic composition of the present invention.

[0198] A "subject" may be a vertebrate, a mammal or a domestic animal. Thus, the compositions and medicaments according to the invention may be used to treat any mammal, such as livestock (e.g., a horse), a pet, or may be used in other veterinary applications. However, most preferably, the subject is a human being.

[0199] A "therapeutically effective amount" of an immunogenic composition refers to the amount required to ameliorate, prevent or treat any given disease when administered to a subject, preferably prophylactically.

[0200] For example, the immunogenic composition of the present invention can be used in an amount of about 0.001 μg to about 1 mg, preferably about 0.001 μg to about 500 μg. Preferably, the amount of the immunogenic composition is about 0.01 μg to about 250 μg, most preferably about 0.1 μg to about 100 μg. Preferably, the immunogenic composition according to the present invention is administered in a dose of 1-50 μg.

[0201] The immunogenic composition of the present invention may further include a pharmaceutically acceptable carrier. The "pharmaceutically acceptable carrier" described herein is any known compound or combination of known compounds known to those skilled in the art that can be used to formulate a pharmaceutical composition.

[0202] In one embodiment, the pharmaceutically acceptable carrier can be solid, and the composition can be in the form of a powder or tablet. Solid pharmaceutically acceptable carriers can include one or more substances, which can also be used as flavoring agents, lubricants, solubilizers, suspending agents, dyes, fillers, glidants, compression aids, inert adhesives, sweeteners, preservatives, dyes, coatings or tablet disintegrants. The carrier can also be an encapsulating material. In powders, the carrier is a subdivided solid mixed with a subdivided active agent according to the present invention. In tablets, the active agent (e.g., the immunogenic composition according to the present invention) can be mixed with a carrier with necessary compression properties in an appropriate ratio and compacted into a desired shape and size. Powders and tablets preferably contain up to 99% of the active agent. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugar, lactose, dextrin, starch, gelatin, cellulose, polyvinyl pyrrolidine, low melting point waxes and ion exchange resins. In another embodiment, the drug carrier can be a gel, and the composition can be in the form of an emulsion or the like.

[0203] However, the pharmaceutical carrier can be a liquid, and the pharmaceutical composition is in the form of a solution. Liquid carriers are used to prepare solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The immunogenic composition according to the present invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier, such as water, an organic solvent, a mixture of the two, or a pharmaceutically acceptable oil or fat. The liquid carrier can contain other suitable pharmaceutical additives, such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickeners, colorants, viscosity modifiers, stabilizers or osmotic pressure regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing the above-mentioned additives, such as cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyols, such as glycols) and derivatives thereof, and oils (such as fractionated coconut oil and peanut oil). For parenteral administration, the carrier can also be an oily ester, such as ethyl oleate and isopropyl myristate. Sterile liquid carriers can be used for sterile liquid form compositions (for parenteral administration). The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

[0204] Liquid pharmaceutical compositions are sterile solutions or suspensions, which can be administered, for example, subcutaneously, intradermally, intrathecally, epidurally, intraperitoneally, intravenously, and particularly intramuscularly. Nucleic acid sequences or expression cassettes of the present invention can be prepared as sterile solid compositions, which can be dissolved or suspended using sterile water, saline or other suitable sterile injectable media when administered.

[0205] The immunogenic compositions of the present invention can be administered orally in the form of sterile solutions or suspensions containing other solutes or suspending agents (e.g., sufficient saline or glucose to make the solution isotonic), bile salts, gum arabic, gelatin, sorbitol monoesters, polysorbate 80 (oleate copolymerized with sorbitol and its anhydride and ethylene oxide), etc. The immunogenic compositions according to the present invention can also be administered orally in the form of liquid or solid compositions. Compositions suitable for oral administration include solid forms such as pills, capsules, granules, tablets and powders, and liquid forms such as solutions, syrups, elixirs and suspensions. Forms that can be used for parenteral administration include sterile solutions, emulsions and suspensions.

[0206] It will be understood that the present invention extends to any nucleic acid or peptide or variant, derivative or analog thereof, which substantially comprises the amino acid or nucleic acid sequence of any sequence mentioned herein, including variants or fragments thereof. The terms "substantially an amino acid / nucleotide / peptide sequence", "variant" and "fragment" may be a sequence having at least 40% sequence identity with the amino acid / nucleotide / peptide sequence of any sequence mentioned herein, for example, 40% identity with a sequence identified as SEQ ID No: 1-27, etc.

[0207] Also contemplated are amino acid / polynucleotide / polypeptide sequences having greater than 65%, more preferably greater than 70%, even more preferably greater than 75%, yet more preferably greater than 80% sequence identity with any of the sequences mentioned. Preferably, the amino acid / polynucleotide / polypeptide sequence has at least 85% identity, more preferably at least 90% identity, even more preferably at least 92% identity, even more preferably at least 95% identity, even more preferably at least 97% identity, even more preferably at least 98% identity and most preferably at least 99% identity with any of the sequences mentioned herein.

[0208] The skilled person will understand how to calculate the percent identity between two amino acid / polynucleotide / polypeptide sequences. In order to calculate the percent identity between two amino acid / polynucleotide / polypeptide sequences, an alignment of the two sequences must first be prepared, and then the sequence identity values ​​are calculated. The percent identity of the two sequences may take different values, depending on: (i) the method used to align the sequences, such as ClustalW, BLAST, FASTA, Smith-Waterman (implemented in different programs), or a structural alignment from a 3D comparison; and (ii) the parameters used by the alignment method, such as local versus global alignment, the pairing score matrix used (e.g., BLOSUM62, PAM250, Gonnet, etc.), and gap penalties, such as function forms and constants.

[0209] Once aligned, there are many different ways to calculate the percent identity between two sequences. For example, the identity figure can be divided by: (i) the length of the shortest sequence; (ii) the length of the alignment; (iii) the average length of the sequences; (iv) the number of non-gap positions; or (v) the number of equivalent positions excluding overhangs. In addition, it will be appreciated that the percent identity is also strongly dependent on length. Thus, the shorter a pair of sequences is, the higher the sequence identity that is expected to occur by chance.

[0210] Therefore, it will be appreciated that accurate alignment of protein or DNA sequences is a complex process. The popular multiple alignment program ClustalW (Thompson et al., 1994, Nucleic Acids Research, 22, 4673-4680; Thompson et al., 1997, Nucleics Acids Research, 24, 4876-4882) is a preferred method for generating multiple alignments of proteins or DNA according to the present invention. Suitable parameters for ClustalW may be as follows: for DNA alignments: Gap start penalty = 15.0, Gap extension penalty = 6.66, and Matrix = Identity. For protein alignments: Gap start penalty = 10.0, Gap extension penalty = 0.2, and Matrix = Gonnet. For DNA and protein alignments: ENDGAP = -1, and GAPDIST = 4. Those skilled in the art will appreciate that these and other parameters may need to be changed to achieve optimal sequence alignment.

[0211] Preferably, the percent identity between two amino acid / polynucleotide / polypeptide sequences can then be calculated based on an alignment such as (N / T)*100, where N is the number of positions at which the sequences share the same residue, and T is the total number of compared positions including gaps and including or excluding overhangs. Preferably, overhangs are included in the calculation. Thus, the most preferred method for calculating the percent identity between two sequences comprises (i) preparing a sequence alignment using the ClustalW program using a suitable set of parameters (e.g., as described above); and (ii) plugging the values ​​of N and T into the following formula: sequence identity=(N / T)*100.

[0212] Those skilled in the art will know alternative methods for identifying similar sequences. For example, a sequence that hybridizes to a DNA sequence or its complement under stringent conditions will encode a substantially similar nucleotide sequence. By stringent conditions, the inventors mean that the nucleotides hybridize to the filter-bound DNA or RNA in 3x sodium chloride / sodium citrate (SSC) at about 45°C, followed by at least one wash in 0.2xSSC / 0.1% SDS at about 20°C-65°C. Alternatively, a substantially similar polypeptide may differ from, for example, a sequence in the amino acid sequence shown in SEQ ID No: 1 to 27 by at least 1 but less than 5, 10, 20, 50 or 100 amino acids.

[0213] Due to the degeneracy of the genetic code, it is obvious that any nucleotide sequence described herein can be changed or altered without substantially affecting the protein sequence encoded therein to provide its functional variant. Suitable nucleotide variants are sequences having different codons encoding the same amino acid in the replacement sequence, thereby producing those nucleotide variants with silent (synonymous) changes. Other suitable variants are those variants having homologous nucleotide sequences but including all or part of the sequence, which are changed by replacing different codons, and these codons encode amino acids with side chains of biophysical properties similar to the amino acids replaced therewith, to produce conservative changes. For example, small non-polar hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline and methionine. Large non-polar hydrophobic amino acids include phenylalanine, tryptophan and tyrosine. Polar neutral amino acids include serine, threonine, cysteine, asparagine and glutamine. Positively charged (basic) amino acids include lysine, arginine and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Thus, it will be understood which amino acids can be replaced with amino acids having similar biophysical properties, and the skilled artisan will be aware of the nucleotide sequences encoding these amino acids.

[0214] All features described herein (including any accompanying claims, abstract and drawings) and / or all steps of any method or process disclosed may be combined with any aspect described above in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive.

[0215] For a better understanding of the invention, and in order to show how embodiments of the invention may be carried into effect, reference will now be made, by way of example, to the accompanying drawings, in which:

[0216] Figure 1 A heat map is shown that visualizes the pairwise identity scores between VP0 protein sequences of 150 rhinovirus strains calculated using the MUSCLE algorithm after hierarchical clustering. Pairwise identity scores above (>59.9%, blue) or below (<59.9%, red) the threshold required for prediction of cross-immunity are shown.

[0217] Figure 2 A circular tree clustering 150 rhinovirus strain VP0 protein sequences into 3 clusters is shown. Of the sequences analyzed, cluster 1 (red) contains all RV-A species VP0 sequences, cluster 2 (black) contains all RV-B species VP0 sequences, and cluster 3 (green) contains all RV-C species VP0 sequences.

[0218] Figure 3is a set of bar graphs showing the number of IFN-γ producing splenocytes from mice immunized with RV-A16 VP0 protein after stimulation with RV-A16 VP0 (A) or the indicated RV-A (B) or RV-B / C (C) peptide pools. Mice were sacrificed 35-49 days after the first immunization, and splenocytes were harvested, stimulated as indicated, and analyzed by ELISPOT for IFN-γ producing splenocytes ( / 10 6 Splenocytes were counted. (A) & (B) n = 24 mice, data are pooled from 3 independent experiments; (C) n = 5 mice. Data are presented as geometric mean ± 95% confidence interval. Significant differences were compared with irrelevant peptides using a linear mixed effects model ***: p < 0.0001; ns: not significant.

[0219] Figure 4 is a set of bar graphs showing the number of IFN-γ producing splenocytes from mice immunized with RV-B06 VP0 protein after stimulation with RV-B06 VP0 (A) or the indicated RV-B (B) or RV-A / C peptide pools (C). Mice were sacrificed 35-49 days after the first immunization, and splenocytes were harvested, stimulated as indicated, and analyzed by ELISPOT for IFN-γ producing splenocytes ( / 10 6 Splenocytes were counted. (A) & (B) n = 24 mice, data are pooled from 3 independent experiments; (C) n = 7 mice. Data are presented as geometric mean ± 95% confidence interval. Significant differences were compared with irrelevant peptides using a linear mixed effects model. ***: p < 0.0001; **: p < 0.001; *p < 0.01; ns: not significant.

[0220] Figure 5 is a set of bar graphs showing the number of IFN-γ producing splenocytes from mice immunized with RV-C07 VP0 protein after stimulation with RV-C07 VP0 (A) or the indicated RV-C (B) or RV-A / B class (C) peptide pools. Mice were sacrificed 35-49 days after the first immunization, and splenocytes were harvested, stimulated as indicated, and analyzed by ELISPOT for IFN-γ producing splenocytes ( / 10 6 Splenocytes were counted. n = 7 mice; data are pooled from 2 independent experiments. Data are presented as geometric mean ± 95% confidence interval. Significant differences were compared with irrelevant peptides using a linear mixed effects model. ***: p < 0.0001; **: p < 0.01; *p < 0.05; ns: not significant.

[0221] Figure 6is a set of dot plots showing the median fragment identity / similarity score for each RV-C strain VP0 sequence among all other RV-C VP0 strains, and the median sequence identity / similarity score for each strain alone for RV-C07. (A) All C strains are plotted as a single cluster. (B) C strains are divided into two clusters.

[0222] Figure 7 is a set of bar graphs showing the number of IFN-γ producing splenocytes from mice immunized with RV-C01 VP0 protein after stimulation with RV-C01 VP0 (A) or the indicated RV-C (B) or RV-A / B class (C) peptide pools. Mice were sacrificed 35-49 days after the first immunization, and splenocytes were harvested, stimulated as indicated, and analyzed by ELISPOT for IFN-γ producing splenocytes ( / 10 6 Splenocytes were counted. n = 7 mice; data are pooled from 2 independent experiments. Data are presented as geometric mean ± 95% confidence interval. Significant differences were compared with irrelevant peptides using a linear mixed effects model. ***: p < 0.0001; **: p < 0.01; *p < 0.05; ns: not significant.

[0223] Figure 8 is a set of bar graphs showing the number of IFN-γ producing splenocytes from mice immunized with RV-C19 VP0 protein after stimulation with RV-19 VP0 (A) or the indicated RV-C (B) or RV-A / B (C) peptide pools. Mice were sacrificed 35-49 days after the first immunization, and splenocytes were harvested, stimulated as indicated, and analyzed by ELISPOT for IFN-γ producing splenocytes ( / 10 6 Splenocytes were counted. N = 12 mice; data are pooled from 2 independent experiments. Data are presented as geometric means ± 95% confidence intervals. Significant differences were compared with irrelevant peptides using a linear mixed effects model. ***: p < 0.0001; **: p < 0.001; *p < 0.01; ns: not significant.

[0224] Fig. 9 is a set of bar graphs showing the number of IFN-γ producing splenocytes from mice immunized with RV-C24 VP0 protein after stimulation with RV-C24 VP0 (A) or the indicated RV-C (B) or RV-A / B (C) peptide pools. Mice were sacrificed 35-49 days after the first immunization, and splenocytes were harvested, stimulated as indicated, and analyzed by ELISPOT for IFN-γ producing splenocytes ( / 10 6Splenocytes were counted. (A) & (B) n = 26 mice, data are pooled from 2 independent experiments; (C) n = 7 mice. Data are presented as geometric mean ± 95% confidence interval. Significant differences were compared with irrelevant peptides using a linear mixed effects model. ***: p < 0.0001.

[0225] Fig.10 Is a line graph representing the titer of anti-RV VP0 antibodies from mice immunized twice with RV-B06, RV-C01, RV-C07, RV-C19 or RV-C24 VP0 proteins or controls (PBS or vaccine adjuvant alone). Sera were collected 42 days after the first immunization, and the titer of immunogen-specific IgG2a was quantified by ELISA. Each curve represents the titer of anti-RV VP0 IgG2a specific for the VP0 protein used to immunize mice (n=7 mice / immunogen, mean + / - SEM). Sera from control immunized mice (adjuvant alone or PBS, n=7 per group) were combined and the corresponding combined sera were tested in each VP0-specific ELISA (mean + / - SEM of VP0 antigen response).

[0226] Fig.11 is a set of bar graphs showing the results of ELISPOT experiments analyzing the expression of rRV-C24 VP0 protein ( Fig.11 B) and adjuvant only (control; Fig.11 A) Cellular immunity induced in cynomolgus monkeys by immunization with other RV strains. Bars represent mean activity / 2x10 of 3 technical replicates. 5 PBMCs + / - SEM.

[0227] Fig.12 IFN-γ secretion in cynomolgus monkeys immunized with rRV-C24 VP0 protein or adjuvant alone (control) in response to stimulation with RV C-species peptide pool ( Fig.12 A) and IL-4 secretion ( Fig.12 B) Bars represent mean activity / 2x10 of 3 technical replicates. 5 PBMCs + / - SEM.

[0228] Fig.13 is a bar graph showing the concentration of RV-C24 VP0 binding IgG in cynomolgus monkey plasma quantified by ELISA at different time points after immunization with rRV-C24 VP0 protein. The bars represent the average IgG concentration and the dots represent individual animal responses. The arrows indicate when the animals were immunized.

[0229] Fig.14Western blot of HEK293 lysates prepared at different time points after transfection with RV VP0 mRNA. The marker lane is designed as M, and the bands at 38 kDa and 28 kDa are marked. The predicted molecular weight of RV VP0 protein is approximately 36 kDa. Fig.14 A is a Western blot of lysates generated from HEK293 cells transfected with RV-A16 VP0 mRNA at 24, 48, 72 or 96 hours post-transfection. A positive control of recombinant RV-A16 VP0 protein was loaded onto the gel (labeled rRV-A16 VP0). RV-A16 VP0 protein was detected using a monoclonal anti-RV-A16 VP0 antibody. Fig.14 B is a Western blot of lysates generated from HEK293 cells transfected with RV-B06 or RV-C24 VP0 mRNA at 24, 48, 72, or 96 hours post-transfection. RV-B06 and C24 VP0 proteins were detected using antisera from mice immunized with recombinant RV-B06 or recombinant RV-C24 VP0 proteins, respectively.

[0230] Fig.15 is a bar graph showing the results of an ELISPOT assay analyzing cellular immunity in mice induced by immunization with RV-C24 VP0 mRNA against other RV strains. The bars represent the average activity of 6 animals / 5x10 5 splenocytes + / - SEM. *p<0.05, ANOVA.

[0231] Fig.16 Is a bar graph showing the concentration of RV-C24 VP0 binding IgG in mouse serum quantified by ELISA at different time points after immunization with RV-C24 VP0 mRNA. The bars indicate the mean IgG concentration + / - SEM. The arrows indicate when the animals were immunized.

[0232] Fig.17 is a bar graph showing the results of an ELISPOT assay analyzing cellular immunity induced by immunization of cynomolgus monkeys with mRNA concatemers consisting of RV-C24 / A16 / B06 VP0 mRNA separated by a 2A peptide coding sequence. Quantification of IFN-γ by ELISPOT ( Fig.17 A) or IL-4 ( Fig.17 B) Secretion. Bars represent mean activity / 2x10 of 3 technical replicates. 5 PBMCs + / - SEM.

[0233] Fig.18 is a bar graph showing the expression of RV-A16 ( Fig.18 A) RV-B06( Fig.18 B) and RV-C24( Fig.18 C) Concentration of VP0 binding IgG, the mRNA concatemer is composed of RV-C24 / A16 / B06 VP0 mRNA separated by 2A peptide coding sequence. Arrows indicate when animals were immunized. Bars indicate IgG concentrations detected in individual animals. Each figure was generated using data from the same animal.

[0234] Fig.19 is a bar graph showing RV-A01 RNA concentration in the lungs of control and RV-A16 VP0 mRNA immunized mice determined by RT-qPCR at 1, 6, and 14 days after infection with RV-A01. The bars represent the mean RV-A01 RNA + / - SEM of 8 animals. *p<0.05, ANOVA.

[0235] Fig. 20 is a bar graph showing the results of an ELISPOT experiment analyzing how cellular immunity in mice immunized with RV-A16 VP0 mRNA responds to subsequent heterotypic RV-A01 infection in splenocytes harvested 14 days after infection with RV-A1. Bars represent the average of 1x10 dot-forming units / 1 of 8 animals. 6 splenocytes + / - SEM. *p<0.05, ***p<0.001, ANOVA.

[0236] Fig.21 is a bar graph showing the results of an ELISPOT assay analyzing cellular immunity in control mice whose spleens were also harvested 14 days after infection with RV-A01. Bars represent the average of 8 animals in dot-forming units / 1x10 6 splenocytes + / - SEM.

[0237] Fig. 22 is a bar graph showing the expression of CD62 in the lungs of RV-A16 VP0 mRNA-immunized mice and control mice after infection with RV-A1. - CD44 + Effector CD4 + ( Fig. 22 A) and CD8 + ( Fig. 22 B) Average number of T cells. Bars represent the average number of cells + / - SEM of 8 animals. **p<0.01, ***p<0.001, ANOVA.

[0238] Fig.23 is a set of related graphs, which plots the expression of RV-A16 VP0 mRNA ( Fig.23 B) or control ( Fig.23 A) The frequencies of Th1 cells and Th2 cells per mouse infected with RV-A1 after immunization.

[0239] Fig.24 is a set of bar graphs showing the CD4 in BAL of control and RV-A16 VP0 mRNA immunized mice at different time points after RV-A1 infection + ( Fig.24 A) and CD8 + ( Fig.24 B)T RM Number of cells. Bars represent mean cell number or mean cell frequency + / - SEM of 8 animals. ****p<0.0001, ANOVA.

[0240] Fig.25 is a set of bar graphs showing the CD4 in BAL of control and RV-A16 VP0 mRNA-immunized mice at different time points after RV-A01 infection. + ( Fig.25 A) and CD8 + ( Fig.25 B)T RM Cell frequency. Bars represent mean cell number or mean cell frequency + / - SEM of 8 animals. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ANOVA.

[0241] Fig.26 is a set of bar graphs showing the CD4 + ( Fig.26 A) and CD8 + ( Fig.26 B)T RM Number of cells. Bars represent mean cell number or mean cell frequency + / - SEM of 8 animals. *p<0.05, **p<0.01, ***p<0.001, ANOVA.

[0242] Fig. 27 is a set of bar graphs showing the CD4 + ( Fig. 27 A) and CD8 + ( Fig. 27 B)T RM Cell frequency. Bars represent mean cell number or mean cell frequency + / - SEM of 8 animals. ****p<0.0001, ANOVA.

[0243] Materials and methods

[0244] Bioinformatic analysis to identify centriolar RV VP0 immunogens

[0245] RV VP0 sequence

[0246] RV VP0 protein sequences were manually extracted from the NCBI protein database using a mixture of blast and annotation searches. Results were refined by comparison with strains annotated in the Taxonomy Browser (NCBI). 150 RV strain VP0 protein sequences were used in the analysis: 78 RV-A sequences, 25 RV-B sequences, and 47 RV-C sequences.

[0247] Alignment, sequence identity and similarity scores

[0248] The 150 RV VP0 sequences were multiple aligned using the MUSCLE (Multiple Sequence Comparison with Logarithmic Expectations) algorithm. Identity and similarity matrices were extracted from the alignments. The identity matrix was used to calculate the percentage of identical amino acids at each position between all paired sequences. The similarity matrix was used to calculate the percentage of amino acids with similar physicochemical properties at each position between all paired sequences.

[0249] Hierarchical clustering

[0250] Using unsupervised hierarchical clustering, the 150 RV strain VP0 sequences were clustered based on the calculated identity scores (converted to distances as required by the method). The tree was then divided into three clusters ( Figure 1 ). From each cluster, the centroid RV VP0 strain sequence (i.e., the central / typical strain or center point) was identified. Each centroid VP0 sequence was defined as the VP0 sequence within that cluster that was predicted to generate the greatest percentage of immune responses against the other strains within that cluster. Centroid identification was performed using the identity threshold range defined as follows.

[0251] Fragment analysis

[0252] The conservation between RV strain VP0 protein sequences was also analyzed at the epitope level by dividing each strain VP0 sequence into 12-mers with one amino acid overlap. Fragment identity was estimated by calculating the percentage of conserved 12-mer segments between VP0 sequence pairs (i.e., "conservation" was defined as 100% identity between two segments). Fragment similarity was estimated by calculating the percentage of similar 12-mer segments; similarity was defined as 80% of the amino acids in a segment being conserved or evolutionarily "interchangeable" according to the BLOSUM62 score).

[0253] RV VP0 protein production and purification

[0254] Table 1 - List of plasmids used to generate different RV VP0 immunogens

[0255] Plasmid ID RV strain VP0 pETSumoRV RVA16 VP0 RV-A16 pETSumoRV-B-DGW2,VP_D RV-B06 pETSumoRV-C1 RV-C01 pETSumoRV-C-DGV2,VP_E RV-C07 pETSumoRV-C19RV RV-C19 RV pETSumoRV-C24 RV-C24

[0256] The same cloning strategy was applied to all recombinant proteins. In brief, each corresponding nucleotide sequence was optimized for E. coli expression, and the synthetic gene was cloned in frame with the SUMO sequence in the T / A cloning site of the pET-SUMO vector and then expressed using the pET-SUMO expression system (Invitrogen). Genes were synthesized and plasmids constructed at Crelux Inc. or Charles River Laboratories.

[0257] Escherichia coli (T7 Express, NEB) was transformed with any of the above plasmids. Expression was performed on a 1-2 liter scale using 2YT medium in a shake flask (Ultra Yield, Thomson). The culture was grown to an OD600nm of 0.8 at 37°C, and the temperature was lowered to 18°C ​​before induction, and protein production was induced by adding 1 mM IPTG. 16 hours after induction, cells were harvested by centrifugation at 4500g for 10 minutes, and the pellet was stored at -80°C or processed immediately.

[0258] After each purification step, the progress of purification was monitored by SDS-PAGE. Purification was performed at 4°C using freezing buffer (buffer components are listed in Table 2 below). The particles were resuspended in buffer A (10 mL / 1 g cells) and crushed at 25 kpsi using a cell crusher (Constant Systems). The lysate was cleared by centrifugation at 38000 g for 30 minutes. The resulting inclusion body particles were washed twice more in the same buffer and solubilized in buffer B (10 mL / 1 g lysed cells) overnight at 4°C by stirring. The solution was then clarified by centrifugation at 38000 x g for 30 minutes and loaded onto two 5 mL HisTrap HP columns (Cytiva™) connected in series, which were balanced in buffer B at 1 mL / min using the Aktaexpress system. The column was washed with buffer B until the baseline was stable, then washed with buffer C for 20 CV and rebalanced to buffer B by a further 20 CV wash. Afterwards, a shallow gradient over 30 CV was applied in buffer D, followed by elution of the protein using buffer E and subsequent HiPrep TM The buffer was immediately exchanged into buffer F using a 26 / 10 desalting column (Cytiva™).

[0259] To remove the His-SUMO-tag, about 0.4 U of SUMO protease (Life sensors) per 1 mg of VP0 protein was added to the eluted protein and incubated at 4°C overnight.

[0260] Use equilibrated in buffer F Affinity gel (Cytiva™) separates the cleaved protein from uncleaved material and proteases by secondary nickel chromatography in gravity flow.

[0261] The flow through was collected, concentrated to approximately 2 mL, and loaded onto a Superdex S200 gel filtration column (Cytiva™) equilibrated at 1 mL / min in buffer F. Fractions containing VPO protein were combined into buffer G for a final overnight dialysis.

[0262] The dialyzed sample was then concentrated to 0.3-0.6 mg / ml and analyzed using the ToxinSensor according to the manufacturer's instructions. TM Chromogenic LAL Endotoxin Assay Kit Endotoxin levels were tested. Samples with protein levels below 5 EU / mg were aliquoted and stored at -80°C.

[0263] Table 2 - Composition of buffers used for RV VP0 protein purification

[0264]

[0265]

[0266] Mouse immunization

[0267] C57BL / 6 mice aged 8-10 weeks were immunized on days 0 and 21 by subcutaneous (SC) route.

[0268] Each mouse was dosed with 10 μg of RV VP0 protein (RV-A16, RV-B06, RV-C01, RV-C07, RV-C19, or RV-C24) and IFA / CpG adjuvant (10 μg CpG 1826 (Invivogen, Toulouse, France) + 100 μl incomplete Freund's adjuvant (IFA Sigma-Aldrich, Gillingham, UK) in a total volume of 100 μl.

[0269] A protein buffer (Tris 20 mM, NaCl 150 mM, arginine 0.5 M pH 8.0) was used as a negative control in the presence or absence of IFA / CpG adjuvant and administered to a control group of mice according to the same procedure.

[0270] Sample processing

[0271] Blood and spleen were collected on day 42. Blood was collected in Vacutainer tubes (BD Vacutainer SST II Nus plastic serum tubes (BD Biosciences, Le Pont De Claix, France), placed at 4°C overnight, and centrifuged at 1660 g for 20 minutes to separate serum from cells. Serum was stored at -20°C.

[0272] Spleens were collected immediately after sacrifice under sterile conditions.

[0273] Cytokine ELISPOT

[0274] Spleens were manually homogenized with a syringe plunger through a cell strainer (BD Biosciences, San Jose, CA) and treated with erythrocyte lysis buffer HybriMax (Sigma-Aldrich, Gillingham, UK) to lyse erythrocytes. Cells were washed twice with RPMI 1640 medium containing HEPES (Gibco, Paisley, UK) supplemented with 2% decomplemented fetal calf serum (FCS) (HYCLONE Hyclone, Logan, Utah), 50 μM 2-mercaptoethanol (Gibco), 2 mM L-glutamine (Gibco), and 100 units / ml of penicillin-streptomycin (Gibco). The cells were counted on a Multisizer and resuspended in complete medium containing RPMI 1640 medium (Gibco) supplemented with 10% decomplemented FCS (HYCLONE), 50 μM 2-mercaptoethanol (Gibco), 2 mM L-glutamine (Gibco), and 100 units / ml penicillin-streptomycin (Gibco). 2×10 5Splenocytes were seeded in 96-well plates (source) and stimulated with peptide pools corresponding to different RV-B06, RV-C01, RV-C07, RV-C19 or RV-C24 full-length VP0 antigens plus 20 U / ml of mouse IL-2. In addition, to evaluate cross-reactivity, splenocytes were also stimulated with peptide pools corresponding to full-length VP0 of a series of RV strains from each RV species, as shown in each figure. Each peptide pool consists of 80 15-mer peptides covering the entire VP0 protein with an overlap of 11 amino acids. The peptide pools were synthesized by Mimotopes and used at a final concentration of 1 μg / ml. Phorbol 12-myristic acid 13-acetate (PMA; Invivogen, Toulouse, France) plus ionomycin (Stemcell, Cambridge, UK) was used as a positive stimulation control. An irrelevant peptide pool (PepMix TM Human (HLA class I Ig-like C1 type domain), from JPT (Berlin, Germany), 15-mer with 11 amino acid overlap) was used as a negative stimulation control. Plates were pre-coated with rat anti-mouse IFN-γ antibody (BD Pharmingen, San Diego, CA) at 1 μg per well in sterile PBS at 4°C overnight and blocked with 10% FCS complete RPMI 1640 medium (Gibco) at 37°C for one hour. Splenocytes were stimulated with 5% CO2 at 37°C for 18 hours.

[0275] After spleen cell stimulation, the plate was washed three times with PBS and then washed three times with 0.05% PBS-Tween. Biotinylated anti-IFN-g (BD Biosciences, Le Pont-De-Claix, France) was added to 0.05% PBS-Tween at 5 mg / mL, 100 mL per well, and the plate was incubated in the dark at 20°C. The plate was then washed 3 times with 0.05% PBS-Tween and incubated in the dark with streptavidin-horseradish peroxidase (SouthernBiotech) in 0.05% PBS-Tween for 1 hour at 20°C.

[0276] Next, the plate was washed three times with 0.05% PBS-Tween and then three times with PBS. 100 μl of substrate solution (3-amino-9-ethylcarbazole, AE, Sigma-Aldrich) was added to each well and the plate was incubated in the dark at 20°C for 15 minutes. The reaction was stopped by adding about 150 μl of distilled water per well. The substrate solution was prepared by mixing the following items: 9Ml distilled water, 1ml acetate buffer, 0.250ml AE and 5 μL H202. The solution was filtered through a 0.22 μm filter (Sigma-Aldrich). Each point corresponding to the T cells secreting IFN-γ was counted using an automatic ELISPOT reader (AID, Strasberg, Germany). The results were expressed as 10 6 The number of IFN-γ spots per splenocyte is shown.

[0277] ELISPOT data for each immunogen were analyzed separately on the log10 scale using a linear mixed model containing fixed effects for study group and treatment group and adjustment for random effects for individual mice. Results for each treatment group are reported on the inverse transformed (antilog) scale using least squares geometric means, least squares geometric mean ratios, 95% confidence intervals, and p-values ​​for individual comparisons. Statistical significance is reported at the 5% significance level (i.e., p<0.05). No adjustment for multiple comparisons was performed because all comparisons were defined a priori and were to a control group (irrelevant peptide).

[0278] ELISA

[0279] Anti-RV VP0 IgG2a responses (or IgG2c responses in 57Bl / 6 mice) were measured by ELISA. Greiner 96-well microplates (Greiner, Gloucestershire, UK) were coated with 100 ng of RV-B06, C19 or C24 VP0 per well in PBS buffer, pH 7.4 (Sigma-Aldrich) at 4°C overnight. Nonspecific sites were blocked for one hour at 37°C with 150 μl of PBS-Tween (PBS pH 7.1, 0.05% Tween 20) plus 1% skim milk per well. Sera were serially diluted 2-fold in VP0-coated plates from a starting dilution of 1:100 or 1:1000 in 0.05% PBS-Tween, 1% milk, incubated for 90 minutes, and washed three times with PBS-Tween.

[0280] RV VP0-specific IgG2a was detected by adding goat anti-mouse IgG2a conjugated with HRP (Southern Biotech, Birmingham, AL) diluted 1:4000 in PBS-Tween plus 1% skim milk to each well and incubating at 37°C for 90 min.

[0281] The plates were then washed three times with PBS-Tween and tetramethylbenzidine (TMB, Tebu-bio laboratories, Le Perray-en-Yvelines, France) substrate solution, 100 mL of which was added to each well. The plates were incubated at room temperature and in the dark for 10-30 minutes. The colorimetric reaction was stopped by adding 100 μl / well of 1M HCl (VWR Prolabo Fontenay-sou-Bois, France). The plates were immediately read at 450 nm and 650 nm on a Versamax plate reader (Molecular Devices).

[0282] In vitro mRNA studies

[0283] Transfection of HEK cells with VP0 mRNA & detection of expressed RV VP0 protein

[0284] HEK293 cells were cultured in DMEM medium supplemented with 10% FCS and 1% penicillin / streptomycin. For transfection, cells were plated on 24-well plates and transfected twice at a fusion rate of about 80%. Cells were transfected with RV VP0 mRNA with mRNA-Fect (RJH Biosciences) according to a pre-optimized protocol consisting of 4 μL of mRNA (Tri-Link), 60 μL of serum-free DMEM medium, and 4 μL of mRNA-fect per well. An untransfected control was included, which consisted of mRNA-fect without any mRNA. Before transfection, each mRNA was diluted to 0.1 mg / mL in RNase-free water (Promega), and mRNA-fect was used as a pure solution of 1 mg / mL according to the manufacturer's recommended protocol. The diluted mRNA (4 μL) was added to 60 μL of DMEM medium and vortexed for 3 seconds. Undiluted mRNA-fect (4 μL per transfection) was then added, and the RNA mixture was vortexed for 10 seconds and then left at room temperature for 30 minutes for complexation. After incubation, the complex (68 μL in total) was added directly to each well of a 24-well plate in duplicate, with a medium volume of 0.5 mL. The cells were then incubated for a period of time (24-96 h) before harvesting. For sample harvesting, the medium was removed, the monolayer was washed in 0.5 mL of PBS pH 7.4, and 100 μL of 2X SDS sample buffer (Invitrogen) was added to two replicate wells. The cells were lysed by pipetting and scraping, and the replicates were then combined to produce 1 sample, and the samples were stored at -80°C. Protein expression was visualized using SDS-polyacrylamide gel electrophoresis (SDS-PAGE, Invitrogen), and the proteins were then transferred to nitrocellulose (Invitrogen) and subjected to Western blotting. Western blotting included probing each membrane with a pooled VP0-specific mouse antiserum (anti-A16, B06 or C24 VP0) diluted 1 / 200 in blocking buffer (5% skim milk in PBS) at 4°C overnight. In some experiments, the membrane was probed with an anti-RV-A16 monoclonal antibody (AntibodiesOnline, catalog number ABIN1000236) diluted 1 / 500 in blocking buffer overnight. After incubation, the membrane was washed 3 times for 5 minutes with shaking in 30-50 mL of washing buffer (PBS pH 7.4, containing 0.1% Tween 20). After washing, an anti-mouse H+L chain IgG-HRP secondary antibody (Invitrogen) diluted 1 / 5000 in blocking buffer was added.The secondary antibody was incubated with shaking for 1 hour, the secondary antibody was removed, and 30-50 mL of washing buffer was added for 30 minutes, and then washed twice with 30-50 mL of washing buffer, each for 5 minutes. After washing, 2 mL of ECL Plus substrate (ThermoScientific) was added for 2 minutes, and the membrane was imaged using a Peqlab imager according to the manufacturer's recommended chemiluminescence protocol.

[0285] Cynomolgus monkey mRNA vaccine research

[0286] All studies were performed in accordance with local laws and regulations and were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC).

[0287] mRNA vaccine preparation

[0288] On the day of use, Transfection reagent and mRNA buffer (both from Polyplus, France) were equilibrated to room temperature. mRNA was diluted to 50 μg / mL in mRNA buffer. An in vivo- Transfection reagent was added and the resulting solution was incubated at room temperature for 15 minutes before use. For control solution, mRNA was replaced with an equal volume of sterile water (Polyplus).

[0289] Cynomolgus monkey immunization

[0290] On days 0 and 21 of the study, each animal received 100 μg of mRNA in a total volume of 2 mL, or 2 mL of transfection control reagent, intramuscularly.

[0291] Blood sampling and preparation of plasma and peripheral blood mononuclear cells

[0292] Blood was collected from the saphenous or cephalic vein on study days 0, 14, 21, 28, 35, and 42. The blood was incubated at room temperature for 30 minutes, then centrifuged, and plasma and peripheral blood mononuclear cells (PBMCs) were prepared by standard methods.

[0293] Plasma ELISA

[0294] 96-well plates were coated with goat anti-rhesus IgG (H+L)-UNLB (Southern Biotech, US) diluted with PBS for standard curves, or 25 μg / well RV VP0 protein diluted with PBS for detection of antigen-specific IgG in monkey plasma samples. The plates were incubated overnight at 4°C. The plates were washed three times with PBS-Tween (PBS containing 0.05% Tween 20 (Sigma-Aldrich)). Nonspecific binding was blocked by incubation with PBS 5% milk (Sigma-Aldrich) for 2 hours at room temperature. The plates were washed three times with PBS-Tween. 100 μL of standard or plasma sample was added to each well, diluted in PBS-1% BSA, and incubated for 2 hours at room temperature. An 11-point standard curve was generated using serial 2-fold dilutions of rhesus IgG-UNLB (Southern Biotech, US) starting from 400 ng / mL. The plates were washed three times with PBS-Tween. Bound antibodies were detected with Fcγ fragment-specific peroxidase AffiniPure goat anti-human IgG (Jackson Immunoresearch, US), which was diluted 1:5000 in PBS 1% BSA (Sigma-Aldrich) and incubated for 1 hour at room temperature. The plates were washed three times with PBS-Tween and then developed using 100 μL TMB substrate per well, incubated for about 10 minutes, and then 100 μL 0.18MH2SO4 per well to stop the reaction. The plates were immediately read at 450 nm using a SpectraMax plate reader (Molecular Devices).

[0295] PBMC ELISpot

[0296] PBMCs were stimulated with peptide pools as described above, with 2x10 5 Each stimulation was performed three times. IFN-γ or IL-4 ELISpot was performed using monkey IFN-γ ELISpot PRO kit (ALP), strips (Mabtech-3421M-2AST-10) and human IL-4 ELISpot PRO kit (ALP) (Mabtech-3410-2APW-10) according to the manufacturer's instructions. The AID ELISpot machine (model ELR088IFL) was used to determine the expression of 2x10 5 The activity of PBMCs.

[0297] Mouse mRNA vaccine research

[0298] mRNA vaccine preparation

[0299] On the day of use, Transfection reagent and mRNA buffer (both from Polyplus, France) were equilibrated to room temperature. mRNA was diluted to 200 μg / mL in mRNA buffer. The transfection reagent was added to the diluted mRNA and the resulting solution was incubated at room temperature for 15 minutes before use. For the control solution, the mRNA was replaced with an equal volume of sterile water (Polyplus).

[0300] Mouse immunization

[0301] On days 0 and 21 of the study, each mouse received 5 μg of RV mRNA vaccine in a total volume of 50 μL, or 50 μL of transfection control reagent, administered intramuscularly.

[0302] Mouse rhinovirus infection

[0303] Each mouse was dosed intranasally (in) with 50 μL of rhinovirus preparation (grown as described in Bartlett et al., 2008, Nat. Med.) or 50 μL of PBS (ThermoFisher Scientific, UK), dropwise into both nostrils under isofluoran anesthesia.

[0304] Mouse sample harvest and processing

[0305] Blood samples were obtained by tail vein puncture at time points before sacrifice and collected using sodium heparinized capillary tubes (Hirschmann- Peripheral blood samples were collected from the jugular vein using sodium heparinized capillary tubes. Whole blood samples were centrifuged to separate serum from cells, and the serum was then stored at -80°C.

[0306] After euthanasia, the trachea was cannulated and bronchoalveolar lavage (BAL) was performed using three 0.5 mL sterile PBS washes per mouse, with a combined total volume of 1.5 mL BAL. Samples were centrifuged at 1500 RPM for 10 minutes at 4°C, and the supernatant was stored at -80°C. Cells were resuspended in 0.2% w / v NaCl to lyse erythrocytes, followed by an equal volume of 1.6% w / v NaCl.

[0307] Lymph nodes and spleens were harvested into R10 medium (RPMI 1640 medium containing 10% fetal calf serum (FCS) and 100 U / mL penicillin / streptomycin (P / S), both ThermoFisher Scientific) and then manually homogenized through a 100 μm filter (Greiner Bio-One, UK). Red blood cells were lysed using ACK lysis buffer (Fisher Scientific, UK), and the cells were then washed twice with R10 medium.

[0308] The right upper lobe and the posterior vena cava lobe of each mouse were harvested into RNAprotect (Qiagen, UK) and stored at -80°C. The remaining lobes were collected into R10 medium, then minced and incubated at 37°C in R10 medium for 30 minutes, which was supplemented with 0.14 Wünsch units / ml Liberase (Roche, UK) and 50 μg / mL DNase1 (Roche). The lung tissue was then manually homogenized through a 100 μm filter (Greiner Bio-One). Red blood cells were lysed using ACK lysis buffer (Fisher Scientific, UK), and the cells were then washed twice with R10 medium.

[0309] The viability of single-cell preparations was assessed using trypan blue (ThermoFisher Scientific) exclusion staining, and total cells were counted using a hemacytometer (Neubauer, Germany).

[0310] Neutralization assay using mouse serum

[0311] Mouse sera were serially diluted 1:2 or 1:3.14 and titrated with RV-A1 (5x10 4 TCID50) were shaken and incubated for 1 hour. Then, the virus serum complex (50 mL per well) was mixed with 150 mL of HeLa cells (3x10 5Cells) were incubated in eight replicates on a flat-bottom 96-well plate. Virus-carrying cells and cells alone were used as controls. In some experiments, anti-RV-A1 guinea pig serum (ATCC catalog number V-113-501-558) was used as a positive control for neutralization by serial 1 to 3.14 dilutions to form a 12-point titration curve. The plates were incubated for 3 days, then the supernatant was discarded and the cell monolayer was stained with 150 ml of crystal violet solution (0.1% in PBS) per well for 10-15 minutes and then gently rinsed under the tap to remove the stain. The stained monolayer was then incubated with 150 mL of 1% SDS solution in PBS per well at room temperature on an orbital shaker for 2 hours to solubilize the stain. The resulting optical density was measured at 560 nm using a SpectraMax plate reader (Molecular Devices, US).

[0312] Lung virus loading

[0313] According to the manufacturer's instructions, use RNA was extracted from whole lung tissue using the mini kit columns and Reverse transcription kit (all from Qiagen, UK) was converted into cDNA. RV was quantified relative to 18S rRNA expression using 50nM forward primer (5'-tgagtcctccggcccctgaatg-3'), 300nM forward primer (5'-gtgaagagccscrtgtgct-3') and 5μM QuantiTect probe (Qiagen), and interpolated using internally generated RV plasmid standards. Quantitative rtPCR was performed using QuantStudio 5 real-time qPCR machine (ThermoFisher Scientific).

[0314] Ex vivo cell stimulation for flow cytometry

[0315] Single cell suspensions of lung or BAL cells were stimulated in the presence of 10 μg / mL Brefeldin A (Enzo Life Sciences, US) in R10 medium containing 40 ng / mL PMA (Invivogen, US) and 3 μg / mL ionomycin (Stemcell Technologies, Canada) or 16 μg / mL RV peptide pool for 4 hours at 37°C. Unstimulated control samples were incubated in R10 medium containing only Brefeldin A.

[0316] Flow cytometry

[0317] Single cell suspensions of lung, BAL or lymph node cells were initially stained with a Fixable Purple Dead Cell Stain Kit (Invitrogen, US) and then stained for 30-60 minutes with anti-mouse surface marker antibodies plus TruStain FcX antibodies diluted in FACS buffer (PBS containing 2% FCS and 2mM EDTA (Fisher Scientific)). Cells were washed twice with FACS buffer and fixed with 1% formaldehyde solution (Sigma-Aldrich, UK) in FACS buffer. For intranuclear staining, cells were fixed with transcription factor staining buffer set (eBioscience, US) and stained for 1 hour with anti-mouse transcription factor and cytokine antibodies diluted in permeabilization buffer (eBioscience). Samples were collected using LSRFortessa (BD, US) and analyzed using FlowJo TM (BD) for analysis.

[0318] ELISA

[0319] Nunc Maxisorp 96-well plates (Fisher Scientific) were coated with 50 ng / well mouse anti-IgG antibody (R&D Systems, US) diluted in PBS for standard curves and 25 μg / well RV-A16, RV-B06 or RV-C24 protein diluted in PBS for detection of antigen-specific IgG in mouse serum samples. The plates were incubated overnight at 4°C. The plates were washed three times with PBS-Tween (PBS containing 0.05% Tween 20 (Sigma-Aldrich)). Nonspecific binding was blocked by incubation with PBS 5% milk (Sigma-Aldrich) for 1 hour at room temperature. The plates were washed three times with PBS-Tween. 50 μL of standard or serum sample was added to each well, diluted in PBS 5% milk, and incubated for 2 hours at room temperature. A 7-point standard curve was generated using a serial 1:3 dilution of the total IgG mouse ELISA standard (Invitrogen) starting from 100 μg / mL. The plates were washed three times with PBS-Tween. The bound antibodies were detected with 25ng / well mouse IgG biotinylated antibodies (R&D Systems) diluted in PBS 1% BSA (Sigma-Aldrich) and incubated at room temperature for 1 hour. The plates were washed three times with PBS-Tween and then incubated for 20 minutes at room temperature with 50ng / well streptavidin-HRP conjugate (Millipore, US). The plates were washed three times with PBS-Tween and then developed using 50 μL TMB substrates (Fisher Scientific) per well, incubated for about 5 minutes, and then 50 μL 0.18M H2SO4 per well was used to stop the reaction. The plates were immediately read at 450nm using a Petromax plate reader (Molecular Devices).

[0320] result

[0321] Identification of centroid RV sequences for use as cross-protective immunogens

[0322] Define thresholds for centroid identification

[0323] Glanville et al. (2013)[6] demonstrated that immunization of mice with VP0 protein from RV-A16 generated cellular immunity that cross-reacted with RV-B14, RV-A1, and RV-A29. The identity scores of RV-B14, RV-A1, and RV-A29 VP0 sequences were calculated for pairwise comparisons with the RV-A16 VP0 sequence (Table 3).

[0324] Table 3 - Sequence and fragment identity and similarity scores from MUSCLE analysis of 150 RV strain VPO protein sequences used to demonstrate cross-immunity in the study of Glanville et al. (2013). Threshold scores are highlighted in bold.

[0325]

[0326] Glanville et al. (2013) [6] demonstrated that immunization of mice with RV-A16 VP0 protein induced cellular immunity that was cross-reactive with RV-A14, RV-A1, and RV-A29. Minimum identity and similarity scores were used as thresholds: any VP0 protein with a sequence identity score >59.9% or a similarity score >84.0% (Table 3) was predicted to generate cross-reactive cellular immunity against each other. Any VP0 protein with an identity score below these thresholds was not predicted to generate cross-reactive immunity against each other.

[0327] A threshold was used to select the centroid VP0 protein from each cluster.

[0328] Identification of the centroid

[0329] Identification of centroids was first performed using sequence identity scores alone, as this is the most stringent approach.

[0330] Figure 1 Figure 2 is a heatmap of sequence identity scores between 150 RV strain VP0 sequences calculated by MUSCLE. Those sequences with identity scores >59.9% are shown in blue. RV-A16 VP0 has previously been shown to be a potential centroid VP0 sequence for the RV-A species. This data confirms that the RV-A16 VP0 sequence has an identity score >59.9% to all other RV-A species strains and is therefore predicted to induce cellular immunity to all other A strains and was selected as the RV-A species centroid immunogen.

[0331] However, the heatmap indicated that RV-A16 VP0 was not predicted to be cross-immune to many RV-B and C species strains. Therefore, hierarchical clustering based on average connectivity was performed to identify additional RV VP0 protein centroids predicted to induce cellular immunity to all other strains. Figure 2Circular tree formed by hierarchical clustering of 140 RV strain VP0 sequences based on identity scores, and divided them into three clusters. Cluster 1 (red) contains all RV-A species sequences, cluster 2 (black) contains all RV-B species strains, and cluster 3 (green) contains all RV-C strains included in the analysis. Based on this analysis, RV-B06 VP0 was selected as the RV-B species centroid because its identity score with all other RV-B species VP0 protein sequences was above the threshold of 59.9% (Table 4). The RV-C species centroid was identified as RV-C07 because it was calculated that this VP0 sequence covered all other RV-C species VP0 protein sequences above the threshold of 59.9% (Table 4).

[0332] Table 4 - Percentage of RV strains within cluster 2 (n=25) and cluster 3 (n=47) predicted to be cross-immunized by RV-B06 VP0 or RV-C07 VP0 at different sequence identity thresholds. The required sequence identity threshold predicted for cross-immunity is highlighted in bold.

[0333]

[0334] Identification of centroids of additional RV-C species

[0335] Next, the inventors investigated the number of IFN-γ-producing splenocytes in mice immunized with RV-A16 VP0 or RV-B06 VP0 protein. Figure 3 and Figure 4 The data presented in 2014 show that when used as immunogens in mice, RV-A16 VP0 and RV-B06 VP0 proteins induce cellular cross-immunity against all other RV-A and RV-B species, respectively ( Figure 3 However, neither RV-A16 nor RV-B06 VP0 immunization induced cellular immunity against RV-C species ( Figure 3 C and 4C). When RV-C07 VP0 was used as the immunogen, the splenocytes of mice immunized with RV-A16 and RV-B06 responded to stimulation with their respective peptides ( Figure 3 Compared with RV-C07, splenocytes from mice immunized with RV-C07 showed a weaker response to peptide pools from other RV-C species ( Figure 5 B). In addition, there was little cross-reactivity with peptide pools from RV-A and B strains ( Figure 5 C). Therefore, further analyses were performed to select new RV-C species VP0 immunogens that would provide good cross-immunity to other RV-C species, but distinct from RV-C07.

[0336] A deeper level of analysis was required to identify RV-C centroids that were distinct from RV-C07 but still predicted to cross-react with all other RV-C species strains. Therefore, a new analysis was performed using all the scores calculated: sequence identity, sequence similarity, fragment identity, and fragment similarity.

[0337] The identity and similarity scores were summarized as the geometric mean of the recorded metrics (+1 was added before taking the logarithm to avoid negative values). This value is called the identity / similarity score, with higher scores indicating greater similarity and identity. Two identity / similarity scores were reported, one for the entire VP0 sequence analysis and another for the fragment analysis: the sequence identity / similarity score was used for comparison with RV-C07 VP0, while the fragment identity / similarity score was used to predict the potential for cross-immunity based on the thresholds calculated previously.

[0338] exist Figure 6 The median fragment identity / similarity score of each RV-C strain VP0 sequence among all other RV-C VP0 strains is plotted against the median sequence identity / similarity score for each strain for RV-C07 alone. When all RV-C class strains were analyzed as a single cluster ( Figure 6 A), RV-C24, C25 and C49 VP0 have the highest median fragment identity / similarity scores among all other RV-C species strains tested, while having a different sequence identity / similarity score from RV-C07. When RV-C species strains are divided into two clusters ( Figure 6 B), RV-C19 VP0 is identified as the potential centroid of the first cluster, and RV-C01 VP0 is identified as the centroid of the second cluster.

[0339] When using non-aggregate sequence identity and similarity to RV-C07 VP0 and VP0 sequences identified by non-aggregate identity and sequence comparison to all RV-C strain VP0s (Table 5), RV-C24 VP0 was selected as the centroid RV-C species VP0 with the best overall balance between predicted cross-strain coverage and dissimilarity to RV-C07 VP0. From the two-cluster analysis, RV-C01 and RV-C19 VP0s were selected for further testing.

[0340] Table 5 - Sequence identity and similarity scores to RV-C07, and fragment identity and similarity scores to all other RV-C species strains tested (n=47). The selected centroids are highlighted in bold.

[0341]

[0342] RV-A16 VP0 immunization

[0343] Figure 3 is a set of bar graphs showing the results of ELISPOT experiments analyzing the cellular immunity induced by immunization of strains of other RV species with RV-A16 VP0 protein. As described above, mice were immunized twice with RV-A16 VP0 protein and adjuvant, and spleens were subsequently harvested. In order to quantify the level of cellular immunity induced by immunization with RV-A16 VP0, spleen cells were isolated and incubated with different stimuli, such as Figure 3 As shown, splenocytes activated by stimulants secreted cytokine IFN-γ, and the degree of IFN-γ secretion was quantified by ELISPOT analysis.

[0344] The results showed that splenocytes from RV-A16 VP0-immunized mice secreted IFN-γ in response to stimulation with a diverse pool of VP0 peptides from a panel of A-class RVs. Figure 3 B). This is in addition to IFN-γ secretion in response to restimulation with the same recombinant RV-A16 VP0 protein used for immunization ( Figure 3 A).

[0345] When splenocytes from RV-A16 VP0-immunized mice were not stimulated with any stimulus (medium only) or stimulated with an irrelevant peptide, the IFN-γ production by splenocytes was negligible ( Figure 3 A and 3B). When the extent of IFN-γ secretion by splenocytes in response to the RV-A peptide pool was statistically compared to the extent of IFN-γ secretion in response to stimulation with an irrelevant peptide, the results were highly significant for all peptide pools tested ( Figure 3 B). These results suggest that immunization of mice with RV-A16 VP0 induces cellular immunity that cross-reacts with other members of the A-class RV. However, no significant IFN-γ secretion was observed when splenocytes from RV-A16-immunized mice were stimulated with a peptide pool corresponding to the VP0 proteins of RV-B and C-class strains ( Figure 3 C). This indicates that RV-A16 immunization does not induce cross-reactive cellular immunity to strains outside the RV-A species.

[0346] RV-B06 VP0 Immunization

[0347] Figure 4 is a set of bar graphs showing the results of ELISPOT experiments analyzing the cellular immunity induced by immunization with RV-B06 VP0 protein. As described above, mice were immunized twice with RV-B06 VP0 protein and adjuvant, and spleens were subsequently harvested. In order to quantify the level of cellular immunity induced by immunization with RV-B06 VP0, spleen cells were isolated and incubated with different stimuli, such as Figure 4As shown, splenocytes activated by stimulants secreted cytokine IFN-γ, and the degree of IFN-γ secretion was quantified by ELISPOT analysis.

[0348] The results showed that splenocytes from RV-B06 VP0-immunized mice secreted IFN-γ in response to stimulation with a diverse pool of B-species RV VP0 peptides. Figure 4 B). This is in response to immunization with RV-B06 VP0 protein ( Figure 4 A) and RV-B06 peptide pool ( Figure 4 B) Supplementation of IFN-γ secretion.

[0349] When splenocytes from RV-B06 VP0-immunized mice were not stimulated with any stimulus (medium only) or stimulated with an irrelevant peptide, the IFN-γ production by splenocytes was negligible ( Figure 4 When the extent of IFN-γ secretion by splenocytes in response to the RV-B peptide pool was statistically compared to that in response to stimulation with an irrelevant peptide, the results were highly significant for all peptide pools tested ( Figure 4 B).

[0350] These results suggest that immunization of mice with RV-B06 VP0 induces cellular immunity that cross-reacts with other members of the B RV species. However, when splenocytes from RV-B06-immunized mice were stimulated with a pool of peptides corresponding to VP0 proteins of RV-A and C species strains, significant IFN-γ secretion was observed only in response to some peptides of the RV-A species strain ( Figure 4 C). This suggests that RV-B06 VP0 immunization induces limited cross-reactive cellular immunity to RV-A species strains, but not to RV-C species.

[0351] To further demonstrate that immunization of mice with RV-B06 VP0 induced immunity, the humoral response to the immunizing antigen was evaluated. As described above, mice were immunized twice with RV-B06 VP0 protein and adjuvant, and serum was subsequently harvested. The amount of RV-B06 VP0-specific antibodies in mouse serum was determined by ELISA. Fig.10 is a set of line graphs showing the levels of anti-RV-B06 VP0 antibodies in sera of immunized mice quantified by ELISA.

[0352] In all mice immunized with RV-B06 VP0, there were high levels of antibodies that specifically recognized RV-B06 VP0, whereas there were no discernible levels in control immunized mice. These results suggest that in addition to the induction of cross-reactive cellular immunity by immunization with RV-B06 VP0, there was also a strong humoral response to the immunizing protein.

[0353] RV-C07 VP0 Immunization

[0354] Figure 5 is a set of bar graphs showing the results of ELISPOT experiments analyzing the cellular immunity induced by immunization with RV-C07 VP0 protein against VP0 peptides of other RV strains. As described above, mice were immunized twice with RV-C07 VP0 protein and adjuvant, and spleens were subsequently harvested. To quantify the level of cellular immunity induced by immunization with RV-C07 VP0, spleen cells were isolated and incubated with different stimuli, such as Figure 5 As shown, splenocytes activated by stimulants secreted cytokine IFN-γ, and the degree of IFN-γ secretion was quantified by ELISPOT analysis.

[0355] The results showed that although splenocytes from RV-C07 VP0-immunized mice secreted IFN-γ ( Figure 5 A), but IFN-γ secretion in response to stimulation with peptide pools corresponding to other RV-C species strains was less pronounced ( Figure 5 B). In addition, there was little cross-reactivity with VP0 peptides from other RV species ( Figure 5 C) Therefore, a more in-depth bioinformatics analysis was performed to identify other VP0 sequences that could serve as centroid immunogens covering RV-C species strains.

[0356] RV-C01 VP0 Immunization

[0357] Figure 7 is a set of bar graphs showing the results of ELISPOT experiments analyzing the cellular immunity induced by immunization with RV-C01 VP0 protein against other RV strains. As described above, mice were immunized twice with RV-C01 VP0 protein and adjuvant, and spleens were subsequently harvested. To quantify the level of cellular immunity induced by immunization with RV-C01 VP0, spleen cells were isolated and incubated with different stimuli, such as Figure 7 As shown, splenocytes activated by stimulants secreted cytokine IFN-γ, and the degree of IFN-γ secretion was quantified by ELISPOT analysis.

[0358] The results showed that splenocytes from RV-C01 VP0-immunized mice secreted IFN-γ in response to stimulation with a diverse pool of C-type RV VP0 peptides. Figure 7 B). This is in response to immunization with RV-C01 VP0 protein ( Figure 7 A) and peptide pool ( Figure 7 B) Supplementation of IFN-γ secretion.

[0359] When the spleen cells of RV-C01 VP0-immunized mice were not stimulated in any way (only with culture medium; Figure 7 A) or stimulated by an irrelevant peptide ( Figure 7 When the extent of IFN-γ secretion by splenocytes in response to the RV-C peptide pool was statistically compared with that in response to stimulation with an irrelevant peptide, the results were highly significant for all peptide pools tested (except the RV-C19 VP0 peptide) ( Figure 7 B).

[0360] These results suggest that immunization of mice with RV-C01 VP0 induces cellular immunity that cross-reacts with other members of the C RV species. Furthermore, when splenocytes from RV-C01-immunized mice were stimulated with a pool of VP0 peptides from strains of other RV species, IFN-γ secretion in response to peptides from both RV-A and B species was significantly increased ( Figure 7 C).

[0361] To further demonstrate that immunization of mice with RV-C01 VP0 induced immunity, the humoral response to the immunizing antigen was evaluated. As described above, mice were immunized twice with RV-C01 VP0 protein and adjuvant, and serum was subsequently harvested. The amount of RV-C01 VP0-specific antibodies in mouse serum was determined by ELISA. Fig.10 is a set of line graphs showing the levels of anti-RV-C01 VP0 antibodies in sera of immunized mice quantified by ELISA.

[0362] In all mice immunized with RV-C01 VP0, there were high levels of antibodies that specifically recognized RV-C01 VP0, whereas there were no discernible levels in control immunized mice. These results suggest that in addition to the induction of cross-reactive cellular immunity by immunization with RV-C01 VP0, there was also a strong humoral response to the immunizing protein.

[0363] RV-C19 VP0 immunization

[0364] Figure 8 is a set of bar graphs showing the results of ELISPOT experiments analyzing the cellular immunity induced by immunization with RV-C19 VP0 protein against other RV strains. As described above, mice were immunized twice with RV-C19 VP0 protein and adjuvant, and spleens were subsequently harvested. To quantify the level of cellular immunity induced by immunization with RV-C19 VP0, spleen cells were isolated and incubated with different stimuli, such as Figure 8 As shown, splenocytes activated by stimulants secreted cytokine IFN-γ, and the degree of IFN-γ secretion was quantified by ELISPOT analysis.

[0365] The results showed that splenocytes from RV-C19 VP0-immunized mice secreted IFN-γ in response to stimulation with a diverse pool of C-type RV VP0 peptides. Figure 8 B). This is in response to immunization with RV-C19 VP0 protein ( Figure 8 A) and peptide pool ( Figure 8 B) Supplementation of IFN-γ secretion.

[0366] When the spleen cells of RV-C19 VP0-immunized mice were not stimulated in any way (only with culture medium; Figure 8 A) or stimulated by an irrelevant peptide ( Figure 8 When the extent of IFN-γ secretion by splenocytes in response to the RV-C peptide pool was statistically compared with that in response to stimulation with an irrelevant peptide, the results were highly significant for all peptide pools tested ( Figure 8 B).

[0367] These results suggest that immunization of mice with RV-C19 VP0 induces cellular immunity that cross-reacts with other members of the C RV species. Furthermore, when splenocytes from RV-C19-immunized mice were stimulated with a pool of VP0 peptides from strains of other RV species, IFN-γ secretion in response to peptides from both RV-A and B species was significantly increased ( Figure 8 C).

[0368] To further demonstrate that immunization of mice with RV-C19 VP0 induced immunity, the humoral response to the immunizing antigen was evaluated. As described above, mice were immunized twice with RV-C19 VP0 protein and adjuvant, and serum was subsequently harvested. The amount of RV-C19 VP0-specific antibodies in mouse serum was determined by ELISA. Fig.10 is a set of line graphs showing the levels of anti-RV-C19 VP0 antibodies in sera of immunized mice quantified by ELISA.

[0369] In all mice immunized with RV-C19 VP0, there were high levels of antibodies that specifically recognized RV-C19 VP0, whereas there were no discernible levels in control immunized mice. These results suggest that in addition to the induction of cross-reactive cellular immunity by immunization with RV-C19 VP0, there was also a strong humoral response to the immunizing protein.

[0370] RV-C24 VP0 immunization

[0371] Fig. 9is a set of bar graphs showing the results of ELISPOT experiments analyzing the cellular immunity induced by immunization with RV-C24 VP0 protein against other RV strains. As described above, mice were immunized twice with RV-C24 VP0 protein and adjuvant, and spleens were subsequently harvested. To quantify the level of cellular immunity induced by immunization with RV-C24 VP0, spleen cells were isolated and incubated with different stimuli, such as Fig. 9 As shown, splenocytes activated by stimulants secreted cytokine IFN-γ, and the degree of IFN-γ secretion was quantified by ELISPOT analysis.

[0372] The results showed that splenocytes from RV-C24 VP0-immunized mice secreted IFN-γ in response to stimulation with a diverse pool of C-type RV VP0 peptides. Fig. 9 B). This is in response to immunization with RV-C24 VP0 protein ( Fig. 9 A) and RV-C24 peptide pool ( Fig. 9 B) Supplementation of IFN-γ secretion.

[0373] When the spleen cells of RV-C24 VP0-immunized mice were not stimulated in any way (only with culture medium; Fig. 9 A) or stimulated by an irrelevant peptide ( Fig. 9 When the extent of IFN-γ secretion by splenocytes in response to the RV-C peptide pool was statistically compared with that in response to stimulation with an irrelevant peptide, the results were highly significant for all peptide pools tested ( Fig. 9 B).

[0374] These results suggest that immunization of mice with RV-C24 VP0 induces cellular immunity that cross-reacts with other members of the C RV species. Furthermore, when splenocytes from RV-C24-immunized mice were stimulated with a pool of VP0 peptides from other RV species, IFN-γ secretion was significantly increased in response to all peptides from both RV-A and B species ( Fig. 9 C). This suggests that RV-C24 VP0 has the potential to induce cross-reactive cellular immunity against all RV species.

[0375] To further demonstrate that immunization of mice with RV-C24 VP0 induced immunity, the humoral response to the immunizing antigen was evaluated. As described above, mice were immunized twice with RV-C24 VP0 protein and adjuvant, and serum was subsequently harvested. The amount of RV-C24 VP0-specific antibodies in mouse serum was determined by ELISA. Fig.10 is a set of line graphs showing the levels of anti-RV-C24 VP0 antibodies in sera of immunized mice quantified by ELISA.

[0376] In all mice immunized with RV-C24 VP0, there were high levels of antibodies that specifically recognized RV-C24 VP0, whereas there were no discernible levels in control immunized mice. These results suggest that in addition to the induction of cross-reactive cellular immunity by immunization with RV-C24 VP0, there was also a strong humoral response to the immunizing protein.

[0377] Recombinant RV-C24 VP0 induces immunogenicity in cynomolgus monkeys

[0378] Cynomolgus monkeys were immunized twice with recombinant RV-C24 VP0 (rRV-C24 VP0) protein with adjuvant or with adjuvant alone (control), and blood was collected 28 days after the first immunization to prepare PBMCs as described above. To quantify the level of cellular immunity induced by immunization with rRV-C24 VP0 protein, PBMCs were incubated with different peptide pool stimuli corresponding to full-length VP0 from different RV strains or controls, as described above. Fig.11 The x-axis in FIG. PBMC activated by the stimulant secretes cytokine IFN-γ, and the secretion level of IFN-γ is quantified by ELISPOT analysis.

[0379] The results showed that PBMCs from rRV-C24 VP0-immunized cynomolgus monkeys secreted IFN-γ in response to stimulation with a diverse panel of VP0 peptide pools from RV species A, B, and C. Fig.11 B). PBMCs from animals immunized with adjuvant only (control) produced negligible IFN-γ in response to stimulation with the VP0 peptide pool ( Fig.11 A).

[0380] When PBMCs from rRV-C24 VP0-immunized cynomolgus monkeys were stimulated with an irrelevant peptide control pool ( Fig.11 B), IFN-γ production was negligible. When PBMCs from control cynomolgus monkeys were stimulated with an irrelevant peptide control pool or a VP0 peptide pool ( Fig.11 A), IFN-γ production was again negligible.

[0381] These results indicate that immunization of cynomolgus macaques with rRV-C24 VP0 induces cellular immunity that cross-reacts with RV strains of the A, B, and C classes.

[0382] To demonstrate the Th phenotype of the cellular immune response, the IFN-γ response of PBMCs from two cynomolgus monkeys immunized with adjuvant alone (control) or rRV-C24 VP0 protein was compared with the IL-4 response by ELISPOT after peptide pool stimulation. IFN-γ is a typical Th1 cytokine, and IL-4 is a typical Th2 cytokine. Fig.12A shows that PBMCs from two cynomolgus monkeys immunized with rRV-C24 VP0 protein (but not with adjuvant alone (control)) secreted IFN-γ in response to stimulation with a peptide pool from species C RV, which was greater than that produced in response to an irrelevant peptide control pool, but IL-4 secretion was negligible ( Fig.12 B).

[0383] To further demonstrate that immunization with rRV-C24 VP0 induced immunity in cynomolgus macaques, humoral responses to the immunizing antigen were evaluated. Fig.13 It is a bar graph of RV-C24VP0 binding IgG in cynomolgus monkey plasma quantified by ELISA at different time points after immunization with rRV-C24 VP0 protein. The results show that immunization with rRV-C24 VP0 induces the production of RV-C24 VP0-specific IgG antibodies, the number of which increases over time, while animals immunized with adjuvant alone (control) do not produce detectable RV-C24 VP0-specific IgG.

[0384] Transfection of HEK293 cells with RV VP0 mRNA

[0385] To demonstrate that RV VP0 mRNA is translated into full-length VP0 protein in cells, HEK293 cells were transfected with different RV VP0 mRNAs as described above.

[0386] Fig.14 A is a Western blot of lysates produced from HEK293 cells transfected with RV-A16 VP0 mRNA at 24, 48, 72 or 96 hours post-transfection. A positive control of recombinant RV-A16 VP0 protein was loaded onto the gel (labeled as rRV-A16 VP0). The results show that transfection of HEK293 cells with RV-A16 VP0 mRNA resulted in expression of RV-A16 VP0 protein, which peaked at 48 hours post-transfection.

[0387] Fig.14 B is a Western blot of lysates generated from HEK293 cells transfected with RV-B06 or RV-C24 VP0 mRNA at 24, 48, 72, or 96 hours post-transfection. The results show that HEK293 cells transfected with RV-B06 VP0 or C24 VP0 mRNA express RV-B06 and RV-C24 VP0 proteins, respectively. The expression of both proteins peaked at 24 and 48 hours post-transfection. By comparing the VP0 band detected using a monoclonal antibody or antiserum with the marker, the correct approximate molecular weight of the VP0 band was observed to be 36 kDa.

[0388] RV VP0 mRNA induces immunogenicity in mice

[0389] Mice were immunized twice with RV-C24 VP0 mRNA, spleens were harvested 42 days after the first immunization, and splenocytes were prepared as described above. To quantify the level of cellular immunity induced by immunization with RV-C24 VP0 mRNA, splenocytes were incubated with peptide pools corresponding to full-length VP0 proteins from different RV strains or control pools, as described above. Fig.15 As shown, splenocytes activated by stimulants secreted cytokine IFN-γ, and the degree of IFN-γ secretion was quantified by ELISPOT analysis.

[0390] The results showed that splenocytes from RV-C24 VP0 mRNA-immunized mice secreted IFN-γ in response to stimulation with a diverse pool of VP0 peptides from C-species RVs. When splenocytes from RV-C24 VP0 mRNA-immunized mice were stimulated with an irrelevant pool of peptides ( Fig.15 ), IFN-γ production was negligible. When the response to the VP0 peptide pool stimulus was statistically compared with the response to an irrelevant peptide pool, the results were significant. These results suggest that immunization of mice with RV-C24 VP0 mRNA induces cellular immunity that cross-reacts with other members of the C class RV.

[0391] To further demonstrate that immunization with RV-C24 VP0 mRNA induced immunity in mice, the humoral response to the immunizing antigen was assessed. Fig.16 It is a bar graph showing the concentration of RV-C24 VP0 binding IgG in mouse serum quantified by ELISA at different time points after immunization with RV-C24 VP0 mRNA. The results showed that immunization with RV-C24 VP0 mRNA induced the production of RV-C24 VP0-specific IgG antibodies, the amount of which increased over time, while control animals did not produce detectable RV-C24 VP0-specific IgG.

[0392] RV VP0 mRNA induces immunogenicity in cynomolgus monkeys

[0393] Fig.17 : is a bar graph showing the results of an ELISPOT assay analyzing cellular immunity induced by immunization with mRNA concatemers consisting of RV-C24 / A16 / B06 VP0 mRNA separated by a 2A peptide coding sequence. Immunization of animals with RV VP0 mRNA concatemers allows determination of immune responses to each antigen.

[0394] Cynomolgus monkeys were immunized twice with RV-C24 / A16 / B06 VP0 mRNA concatemers or controls, and blood was collected 28 days after the first immunization and PBMCs were prepared as described above. To quantify the level of cellular immunity to each antigen induced by immunization with RV-C24 / A16 / B06 VP0 mRNA concatemers, PBMCs were incubated with peptide pools corresponding to full-length RV-A16, B06, C24 VP0 or control irrelevant peptide pools and IFN-γ ( Fig.17 A) or IL-4 ( Fig.17 B) secretions were incubated together.

[0395] The results showed that PBMCs from cynomolgus monkeys immunized with RV-C24 / A16 / B06 concatemer VP0 mRNA secreted IFN-γ in response to stimulation with VP0 peptide pools corresponding to full-length RV-A16, B06, and C24 VP0. When PBMCs from monkeys immunized with RV-C24 / A16 / B06 concatemer VP0 mRNA were stimulated with an irrelevant peptide pool, the production of IFN-γ was negligible. PBMCs from control immunized animals produced negligible IFN-γ in response to stimulation with the RV VP0 peptide pool or the irrelevant peptide control pool. Fig.17 The results in A show that immunization of cynomolgus monkeys with RV-C24 / A16 / B06 concatemer VP0 mRNA induces cellular immunity to each of the three antigens generated by the VP0 mRNA concatemers.

[0396] To demonstrate the Th phenotype of the cellular immune response, the IFN-γ response of PBMCs from cynomolgus macaques immunized with RV-C24 / A16 / B06 VP0 mRNA concatemers was compared by ELISPOT with that of IL-4, a typical Th1 cytokine and a typical Th2 cytokine. Fig.17 B shows that, compared with IFN-γ( Fig.17 A) In contrast, PBMCs of cynomolgus macaques immunized with RV-C24 / A16 / B06 concatemer VP0 mRNA produced negligible IL-4 in response to stimulation with RV VP0 or control peptide pools. This result suggests that the cellular immune response elicited by RV-C24 / A16 / B06 concatemer VP0 mRNA is Th1 polarized.

[0397] To further demonstrate the induction of immunity by immunization of cynomolgus monkeys with RV VP0 mRNA, the humoral responses to each antigen generated by RV-C24 / A16 / B06 VP0 mRNA concatemers were determined.

[0398] Fig.18is a bar graph showing the expression of RV-A16 ( Fig.18 A) RV-B06( Fig.18 B) and RV-C24( Fig.18 C) Concentration of VPO-binding IgG. These results show that immunization with RV-C24 / A16 / B06 VPO mRNA concatemers induced the production of RV-VPO-specific IgG antibodies against each of the three RV antigens in the concatemers in cynomolgus monkeys.

[0399] Efficacy of RV VP0 mRNA immunization in mice

[0400] To demonstrate that immunization with RV VP0 mRNA confers protection against subsequent heterotypic RV infection, mice were immunized with RV-A16 VP0 mRNA and then infected intranasally with RV-A1, a heterotypic A-class RV strain of the immunized strain, as described above.

[0401] Fig.19 is a bar graph showing the concentration of RV-A1 RNA in the lungs of control and RV-A16 VP0 mRNA immunized mice as determined by RT-qPCR. The results show that while control and immunized mice had similar levels of viral RNA in the lungs one day after infection, by day six, immunized mice had significantly less viral RNA than control mice. By day 14, viral RNA concentrations were negligible in both groups of animals. This result suggests that immunization with RV VP0 mRNA accelerates the clearance of heterotypic RV infection in the lungs of mice.

[0402] RV VP0 mRNA induces cellular immunity

[0403] To demonstrate how immunization with RV VP0 mRNA protects mice from RV infection, the inventors harvested spleens of mice that had been immunized with RV-A16 VP0 mRNA or control and then infected with heterotypic RV-A1 14 days after infection and formed splenocytes. Splenocytes were stimulated with a pool of peptides corresponding to full-length VP0 from a diverse set of strains covering each RV or a control irrelevant peptide pool. IFN-γ secretion in response to peptide stimulation was measured by ELISPOT.

[0404] Fig. 20 The results presented are surprising, indicating that splenocytes from mice immunized with RV-A16 VP0 mRNA and then infected with RV-A1 secrete IFN-γ in response to stimulation with a pool of VP0 peptides from a wide range of RV strains, covering species A, B, and C. The results were highly significant when the results obtained with the VP0 peptide pool were statistically compared to those obtained with an irrelevant peptide control pool.

[0405] In contrast, Fig.21 As shown, in control mice, splenocytes secreting IFN-γ were negligible after stimulation with RV VP0 or control peptide pools. Fig. 20 and 21 The results in show that immunization with VP0 mRNA from a single RV strain produces surprising cross-strain cellular immunity.

[0406] To further demonstrate the mechanism by which RV VP0 mRNA immunization protects mice from RV-A1 infection, the inventors performed immunophenotyping of the lungs of RV-A16 VP0 mRNA-immunized and non-immunized mice after infection with RV-A1. The method was as described above.

[0407] Fig. 22 is a bar graph showing the expression of CD62 in the lungs of RV-A16 VP0 mRNA-immunized mice and control mice after infection with RV-A1. - CD44 + Effector CD4 + ( Fig. 22 A) and CD8 + ( Fig. 22 B) Average number of T cells. The results showed that the effector CD4 T cells in the lungs of immunized mice increased 6 and 14 days after infection. + and CD8 + There were significantly more T cells than in control mice.

[0408] RV VP0 mRNA immunization induces Th1 polarized T cell immunity

[0409] To determine the Th phenotype elicited by RV VP0 mRNA immunization, lungs were harvested from mice infected with RV-A1 after immunization with RV-A16 VP0 mRNA or control. Single cell populations were prepared from the lungs, and cells were incubated with peptide pools corresponding to full-length VP0 from RV-A1. Intracellular cytokine staining flow cytometric analysis was performed to measure the frequency of Th1 and Th2 cells as described.

[0410] Th1 cells are recognized as T-bet + IFN-γ + CD4 + cells, and Th2 cells were identified as Gata3 + IL-4 + CD4 + cell. Fig.23 are a set of correlation graphs in which the frequency of Th1 cells is plotted against the frequency of Th2 cells for each animal following stimulation of lung cells with the RV-A1 VP0 peptide pool.

[0411] The results showed that the frequency of RV-A1 VP0-reactive Th1 cells was higher than that of RV-A1 VP0-reactive Th2 cells in the lungs of immunized mice ( Fig.23 B). In control mice ( Fig.23 A), the opposite situation was observed, in which the proportion of Th2 cells was greater than that of Th1 cells. This result suggests that RV VP0 mRNA triggered a Th1-polarized T cell response and that RV-reactive CD4 T cells of Th1 phenotype were expressed in the lungs of immunized mice. + The proportion of T cells was higher than that of Th2 phenotype.

[0412] RV VP0 elicits tissue-resident T cell memory

[0413] A key component of protective cellular immunity elicited by natural respiratory virus infection is tissue-resident memory T cells (T cells) in the airway mucosa and lungs. RM ) are formed. These T RM The cells rapidly proliferate and clear subsequent infections.

[0414] To determine whether RV VP0 mRNA vaccine delivered intramuscularly could elicit T cells in the airways and lungs of immunized mice. RM To characterize the formation of cells, bronchoalveolar lavage (BAL) and lungs were harvested from mice infected with RV-A01 following immunization with RV-A16 VP0 mRNA or control. Single cell populations were prepared from the lungs and immunophenotyped for CD4 + and CD8 + T RM Cells are identified and counted. + and CD8 + T RM Cells were identified as CD103 + 、CD69 + 、CD4 + or CD103 + 、CD69 + 、CD8 + cell.

[0415] Fig.24 is a set of bar graphs showing the CD4 in BAL of control and RV-A16 VP0 mRNA immunized mice at different time points after RV-A1 infection + ( Fig.24 A) and CD8 + ( Fig.24 B)T RM The results showed that the number of effector CD4 cells in the BAL of immunized mice six days after infection was higher than that in control mice. + and CD8 + TRM There are significantly more cells.

[0416] Fig.25 is a set of bar graphs showing the CD4 in BAL of control and RV-A16 VP0 mRNA immunized mice at different time points after RV-A1 infection + ( Fig.25 A) and CD8 + ( Fig.25 B)T RM The results showed that in the BAL of immunized mice six and fourteen days after infection, compared with control mice, CD4 + and CD8 + T RM Total CD4 + or CD8 + The proportion in cells was significantly higher.

[0417] Fig.26 is a set of bar graphs showing the CD4 + ( Fig.26 A) and CD8 + ( Fig.26 B)T RM The results showed that in the lungs of immunized mice, there were significantly more CD4 + T RM cells, and there were significantly more CD8 + T RM cell.

[0418] Fig. 27 is a set of bar graphs showing the CD4 + ( Fig. 27 A) and CD8 + ( Fig. 27 B)T RM The results showed that in the lungs of immunized mice six and fourteen days after infection, CD4 + and CD8 + T RM Total CD4 + or CD8 + The proportion in cells was significantly higher.

[0419] These results suggest that intramuscular administration of RV VP0 mRNA vaccine elicits T cell proliferation in the airways and lungs of mice. RMWhen the cells were subsequently infected with heterotypic RV strains, the T cells elicited by the vaccine RM Cells proliferate rapidly.

[0420] in conclusion

[0421] The inventors have identified RV VP0 proteins from a single representative strain that are capable of eliciting a broad cellular immune response that cross-reacts with other RV strains of the same species. In particular, as shown in Example ( Figure 3 , 4 , 5, 7, 8 and 9), spleen cells from RV-A16 immunized mice cross-reacted with VP0 peptides from other RV-A species strains, RV-B06 VP0 immunized mice cross-reacted with VP0 peptides from other RV-B species members and peptides from some RV-A species strains, and spleen cells from RV-C01, RV-C19 or RV-C24 VP0 immunized mice cross-reacted with peptides from other RV-C species members. In addition, immunization with VP0 protein from the RV-C species obtained cellular immunity that recognized VPO peptides from both RV-A and RV-B species. Therefore, the immunogenic composition according to the present invention, which includes VP0 peptides selected from RV-A16, RV-B06, RV-C01, RV-C19 and RV-C24 (in any combination), can be used to immunize humans against infection by all RV strains.

[0422] In addition, the inventors have demonstrated that immunization with mRNA encoding the RV VP0 peptide elicits a broad range of cellular immune responses. Fig.15 As shown, the inventors demonstrated that immunization of mice with RV-C24 VP0 mRNA induces cellular immunity that cross-reacts with other members of the C class of RV.

[0423] Thus, advantageously, the immunogenic composition according to the invention overcomes the problem of antigenic heterogeneity between RV strains, which has so far hampered the development of RV vaccines. Furthermore, the immunogenic composition is particularly effective because vaccination with RVVPO antigen will provide protection for patients with chronic lung disease and therefore at risk of RV-induced exacerbations, thereby reducing the associated morbidity, mortality and medical burden.

[0424] References

[0425] 1. Gern, JE The ABCs of rhinoviruses, wheezing, and asthma. Journal of virology 84, 7418–7426 (2010).

[0427] 2.Ritchie,A.I.et al.Pathogenesis of viral infection in exacerbationsof airway disease.Annals of theAmerican Thoracic Society 12,S115–S132(2015).

[0428] 3.Hewitt,R.et al.The role of viral infections in exacerbations ofchronic obstructive pulmonary

[0429] disease and asthma.Therapeutic advances in respiratory disease 10,158–174(2016).

[0430] 4.Choi,T.et al.Enhanced neutralizing antibody responses to rhinovirusc and age-dependent patternsof infection.American Journal of Respiratory andCritical Care Medicine 203,822–830(2021).

[0431] 5.Palmenberg,A.C.&Gern,J.E.Classification and evolution of humanrhinoviruses.Methods in

[0432] Molecular Biology 1221,(2015).

[0433] 6.Glanville,N.et al.Cross-Serotype Immunity Induced by Immunizationwith a Conserved

[0434] Rhinovirus Capsid Protein.PLOS Pathogens 9,e1003669(2013).

[0435] 7.Esquivel A,et al.Effects of Omalizumab on Rhinovirus Infections,Illnesses,and Exacerbations

[0436] of Asthma.Am J Respir Crit Care Med.Oct 15;196(8):985-992(2017).

Claims

1. An immunogenic composition comprising at least one isolated human rhinovirus (RV) VP0 peptide, or an isolated polynucleotide encoding the peptide, wherein the peptide is selected from the group consisting of: RV-C VP0 peptide; RV-B VP0 peptide; RV-A28 VP0; and RV-A89 VP0, or variants or fragments thereof.

2. The immunogenic composition according to claim 1, wherein The immunogenic composition comprises at least two isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-C VP0 peptide; RV-B VP0 peptide; RV-A28 VP0; and RV-A89 VP0.

3. The immunogenic composition of claim 1 or claim 2, wherein the immunogenic composition comprises at least three isolated human rhinovirus (RV) VP0 peptides, or isolated polynucleotides encoding the peptides, wherein the peptides are selected from the group consisting of: RV-C VP0 peptide; RV-B VP0 peptide; RV-A28 VP0; and RV-A89 VP0.

4. The immunogenic composition according to any one of the preceding claims, wherein the RV-C VPO peptide is selected from the group consisting of: RV-C07 VPO; RV-C19 VPO; RV-C24 VPO; and RV-C01 VPO, or variants or fragments thereof.

5. The immunogenic composition according to any one of the preceding claims, wherein the RV-B VPO peptide is RV-B06 VPO.

6. The immunogenic composition according to any one of the preceding claims, wherein the immunogenic composition further comprises an isolated RV-A16 VP0 peptide and / or an isolated RV-A29 VP0 peptide, or an isolated polynucleotide encoding said peptide, or a variant or fragment thereof.

7. The immunogenic composition according to any of the preceding claims, wherein the fragment of the at least one RV VP0 peptide comprises or consists of the corresponding VP2 peptide and / or VP4 peptide.

8. The immunogenic composition according to any one of the preceding claims, wherein at least two or more of the RV VPO peptides form a fusion peptide.

9. The immunogenic composition according to any one of the preceding claims, wherein the polynucleotide comprises a nucleic acid sequence encoding the peptide, preferably wherein the nucleic acid sequence is controlled by elements necessary for its expression in mammalian cells.

10. The immunogenic composition of claim 9, wherein the nucleic acid is DNA or RNA, optionally wherein the RNA is messenger RNA (mRNA) or self-amplifying RNA (saRNA).

11. The immunogenic composition of any one of the preceding claims, wherein the isolated polynucleotides encode at least two or more of the RVVPO peptides, or wherein at least two or more of the RV VPO peptides are encoded by multiple separate polynucleotides.

12. The immunogenic composition of any one of the preceding claims, wherein the immunogenic composition comprises an isolated polynucleotide encoding the RV-C24 VPO peptide, an isolated polynucleotide encoding the RV-A16 VPO peptide, and an isolated polynucleotide encoding the RV-B06 VPO peptide.

13. The immunogenic composition of any one of the preceding claims, wherein the at least one RV VP0 peptide comprises an amino acid sequence substantially as described in any one of SEQ ID No: 1, SEQ ID No: 4, SEQ ID No: 7, SEQ ID No: 10, SEQ ID No: 13, SEQ ID No: 16, SEQ ID No: 19, SEQ ID No: 22 and / or SEQ ID No: 25, or a variant or fragment thereof.

14. An immunogenic composition according to any one of the preceding claims, wherein the isolated polynucleotide comprises a nucleotide sequence substantially as described in any one of SEQ ID No:2, SEQ ID No:3, SEQ ID No:5, SEQ ID No:6, SEQ ID No:8, SEQ ID No:9, SEQ ID No:11, SEQ ID No:12, SEQ ID No:14, SEQ ID No:15, SEQ ID No:17, SEQ ID No:18, SEQ ID No:20, SEQ ID No:21, SEQ ID No:23, SEQ ID No:24, SEQ ID No:26 and / or SEQ ID No:27, or a variant or fragment thereof.

15. The immunogenic composition according to any one of the preceding claims, wherein the immunogenic composition further comprises an adjuvant.

16. The immunogenic composition of any one of the preceding claims, wherein the immunogenic composition is a vaccine.

17. An immunogenic composition according to any preceding claim for use in therapy or prevention.

18. The immunogenic composition according to any one of claims 1 to 16, for use in eliciting an immune response, preferably an immune response against rhinovirus infection.

19. The immunogenic composition for use according to claim 18, wherein the immunogenic composition elicits an immune response against at least one, at least two or at least three rhinoviruses, more particularly against RV-A, RV-B and / or RV-C.

20. The immunogenic composition for use according to claim 18 or claim 19, wherein the immunogenic composition elicits an immune response against at least one strain of RV-A, at least one strain of RV-B and / or at least one strain of RV-C.

21. The immunogenic composition for use according to any one of claims 18 to 20, wherein the immunogenic composition elicits an immune response against the common cold, virally induced wheezing diseases, asthma attacks, bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis and / or chronic fibrotic lung diseases.